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Cardiovascular disease  
Cardiovascular disease (CVD) is currently the number one cause of death 
worldwide1. Over the last decade, CVD-related death has increased by 12.5%2 and 
in fact, one out of three deaths worldwide is now attributable to CVD1,3.  Globally, 
most CVD deaths can be explained by ischemic heart disease (49.8%) and stroke 
(35.3%), followed by hypertensive heart disease, atrial fibrillation and peripheral 
vascular disease1. The major underlying cause for the development of CVD is 
atherosclerosis, the buildup of lipid-loaded plaques in the inner lining of an artery4. 
Atherosclerotic plaques can ultimately rupture and lead to the formation of a blood 
clot, resulting in the obstruction of blood flow in heart (ischemic heart disease), 
brain (stroke) or peripheral tissue (peripheral artery disease). CVD has become an 
obvious economic burden, as the European Heart Network has estimated the total 
CVD-related costs to be €210 billion per year5. Next to the costs generated by the 
healthcare of CVD patients (healthcare, medication, hospitalization) and indirect 
costs (patient work productivity loss), there are also costs associated with 
cardiovascular disease research6. Between 2010 and 2012, around €876 million was 
attributed to CVD research projects6, all trying to better understand and predict the 
development of CVD. However, current prediction models often underestimate and 
overestimate CVD risk in high-risk profiles and low-risk profiles, respectively7.  
In the below paragraphs we will address on the main CVD risk factors and risk 
predictors/calculators. Next, we will discuss the ontogenesis of atherosclerosis, the 
main cause of CVD, with special emphasis on the role of the immune system in this 
disease. Lastly, we will address the use of a new high throughput analytical 
technique to study the immune system (mainly focusing on macrophages) in the 
development and prediction of CVD.  
CVD risk factors  
Before the 20th century, there was no clear way to predict the clinical consequences 
of plaque rupture and the only focus of CVD research was the treatment options. 
From 1950 onwards, several epidemiological studies have enabled a change in the 
research focus, aiming for better definition of accurate risk factors to use in risk 
prediction and disease prevention, rather than only treatment1,8,9. Nine main risk 
factors, including age, gender, dyslipidemia, blood pressure, smoking pattern, 
obesity, diabetes mellitus10 and accounting for more than 90% of myocardial 
infarction (MI) and stroke, have been described by the INTERHEART1,11 and the 
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INTERSTROKE1,12 case-control studies, respectively. The Framingham heart study, 
which started in 1948, investigated the life-time risk of coronary heart disease 
(CHD) and established the Framingham Risk Score, reflecting the 10-year risk of 
developing CHD based on several risk factors, including age, sex, cholesterol levels, 
blood pressure and smoking pattern. In the INTERHEART study, dyslipidemia was 
the main individual predictor for the development of MI11, whereas hypertension 
was the most important  risk factor for stroke in the INTERSTROKE study12. Most 
individuals in the general population have at least one CHD risk factor, and CHD 
event risk score increases greatly in individuals having more than one risk factor13–
15. Of all CVD risk factors, the five leading modifiable ones (dyslipidemia, 
hypertension, smoking pattern, obesity, and diabetes) account for around 50% of 
CVD-related death16. Below the latter risk factors will be discussed in more detail. 
Dyslipidemia  
Dyslipidemia is defined as an abnormal blood lipid concentration, including high 
triglycerides (TG) level, low high-density lipoproteins cholesterol (HDL) and 
elevated total (TC) or low-density lipoprotein (LDL) associated cholesterol17. To be 
transportable in blood, TG and LDL bind to apolipoproteins to form lipoproteins. 
Increased levels of TC, LDL and Apolipoprotein B have all been associated with high 
CVD risk and reducing LDL levels with statin treatment was repeatedly shown to 
reduce the risk for CVD development1,18–20. More recently, treatment with 
proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies showed a 60% 
reduction of LDL concentration, resulting in a 15% decrease in cardiovascular 
events on top of statins19,20. Furthermore, there is genetic evidence that elevated 
blood LDL concentration associates with CVD. Indeed, familial 
hypercholesterolemia (FH) is a genetic condition where LDL levels are abnormally 
high due to mutations in genes such as APOB, LDLR or PCSK921. Patients suffering 
from FH have a higher risk for the development of CVD21. On the other hand, HDL 
is strongly and inversely correlated to CVD but clinical trials raising plasma HDL 
concentration so far failed to reduce CVD burden22. Next to the conventional 
aforementioned lipids measured to determine CVD risk, novel analytical techniques 
have allowed the identification and measurement of other lipid species that are 
potentially more specific for the prediction of CVD23. The lipidomics field has 
allowed the detection of other lipid classes independently linked to the 
development of CVD24,25, as well as the total lipidome profile26–29.  
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Hypertension  
High blood pressure is widely accepted to be one of the strongest risk factor for 
CVD2,30. Hypertension accounts for 54% of stroke and 47% of ischemic heart disease 
worldwide31. Elevated systolic blood pressure is the best predictor of CVD in 
individuals over 50 years old32, while both high systolic and diastolic blood pressure 
can be used as predictors in youngers individuals33. Furthermore, the benefit of 
antihypertensive therapies have been extensively acknowledged in several 
randomized controlled trials34,35. Indeed, reduction of 10 mm Hg by five different 
blood pressure lowering drug led to 20% risk reduction for major CVD events36.  
Smoking pattern 
Smoking is a strong, modifiable risk factor for CVD. According to the WHO, 1.1 
billion people worldwide were smoking in 201537. In the INTERHEART study, current 
smoking was one of the strongest risk factors for the development of acute 
myocardial infarction (MI), accounting for 36% of the risk11. Moreover, there was a 
linear relationship between the number of cigarettes smoked per day and the odds 
of developing MI11. Duration of smoking is also an important determinant for CVD 
risk. Smoking fewer cigarettes/day for a longer time is associated with higher CVD 
risk than smoking more cigarettes/day for shorter time38. Smoking is a stronger risk 
predictor in women than in men, increasing CVD risk by six-fold versus three-fold, 
respectively when compared to never-smokers39. Moreover, cessation of smoking 
for one year already leads to a 50% risk reduction, which is further decreased after 
two years, to reach risk levels of non-smokers40,41.  
Obesity 
Over the last 40 years, the prevalence of hypertension, smoking behavior and blood 
lipid levels have substantially reduced worldwide (31 to 15%, 39 to 26% and 34 to 
17%, respectively)42–44. On the other hand, obesity prevalence almost tripled since 
197545,46 and this increase was associated with a rise in (diagnosed) type 2 diabetes 
mellitus (T2DM) prevalence42. Obesity is defined as a Body Mass Index (BMI) ≥ 30 
kg/m2 and is subdivided in three classes, class I (BMI= 30-34.9, mild obesity), class 
II (BMI=35-39.9, moderate obesity) and class III (BMI≥ 40, severe obesity). 
According to the World Health Organization (WHO) in 2016, 39% of adults were 
overweight (BMI≥25), of which 13% were obese, reaching 650 million individuals45. 
Since 1975, obesity prevalence has nearly tripled and is expected to reach 21% by 
2025 if this trend continues45. Obesity has been repeatedly shown to be an 
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independent risk factor for the development of CVD, as judged its correlation to 
CVD in absence of any other CVD risk factor47.  
Obesity has direct and indirect effects on CVD risk, mediated by a functional 
adaptation of the fat mass and the effects on other CVD risk factors.  Regarding the 
former, obese individuals have excessive fat mass, also known as adipose tissue, 
and this accumulation of fat mass is directly linked to the development of 
atherosclerosis48. In lean individuals, a series of hormones, most commonly known 
as adipokines, are secreted by adipose tissue 47,49. Adipokines  are involved in 
glucose and lipid metabolism, inflammation and coagulation pathways and can 
either be pro- or anti-atherogenic50. During obesity, this adipose tissue secretion 
pattern is dysregulated and shifts toward a pro-atherogenic phenotype, where 
adipokines such as leptin, TNF-α, IL-6 and MCP-1 are overexpressed and contribute 
to the low-grade inflammatory state observed in obesity49,51. These pro-
inflammatory adipokines have been positively associated to the development of 
CVD52. On the other hand, major cardioprotective adipokines including adiponectin, 
omentin and apelin, are downregulated during obesity and hence negatively 
correlated to the development of CVD50,52. Apart from this direct association, 
obesity is also indirectly linked to CVD due to its strong relationship with other CVD 
risk factors, such as  dyslipidemia, hypertension and T2DM53. In 2017, more than 
80% of T2DM cases were overweight or obese54. 
Diabetes 
Diabetes Mellitus (DM) is a well-known risk factor for CVD, as it is independently 
associated with a two to four-fold increased risk for CVD55. DM prevalence keeps 
on increasing, affecting 382 million individuals in 201456. The relationship between 
DM and CVD is complicated, as other CVD risk factors, such as obesity, hypertension 
and dyslipidemia, are often observed in patients with DM. Diabetes is closely linked 
to obesity, as one kilogram weight gain increases the risk to develop diabetes by 
4,5 to 9%57,58. Furthermore, the prevalence of obese among T2DM patients ranges 
from 60% to 90% of all T2DM patients54. Glycemic control drugs have shown to help 
reduce CVD59, however this effect was reported to be modest and mostly due the 
consequences on other risk factors56,59,60.  
Cardiovascular risk assessment  
To assess the most effective treatment for high risk CVD patients, clinicians often 
use CVD risk calculators. To date, there are over 100 cardiovascular risk calculators 
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available61 which are all based on the aforementioned traditional CVD risk factors. 
However, only 25 of these CVD risk prediction models have been externally 
validated in an independent cohort61,62. The most widely known CVD risk calculator 
is the Framingham risk score, derived from the Framingham study (FRS) in 1991. 
The FRS has been validated in 35 US cohorts, with area under the curve (AUC, or 
prediction power value) ranging from 0.60 to 0.83 and in 68 European populations 
with an AUC ranging from 0.53-0.8862. However, comparison between 25 different 
risk calculators in a similar population only revealed a 67% agreement between 
models63. This shows that the output of risk calculators markedly differs, depending 
on the population used to generate the score, but also on the clinical endpoints and 
the length of the calculated risk. Together, this emphasizes that CVD risk 
assessment for every individual patient should be done with a risk calculator, 
derived from a representative population, matching with the patient in question.  
Atherosclerosis: definition 
Atherosclerosis is the main underlying cause for CVD8, and it is defined as a chronic, 
progressive disease typified by the accumulation of inflammatory cells, lipids and 
fibrous tissue in the inner wall of a medium to large sized artery. This so-called 
atherosclerotic plaque can ultimately rupture and lead to the formation of a blood 
clot, which in turn will restrict blood flow to a specific organ, such as the brain or 
the heart. Atherosclerosis is not a modern disease, as it has been observed in 4000 
year-old mummies64,65. It was recognized for the first time in the beginning of the 
19th century, by the French pathologist Jean Lobstein66. Initially, atherosclerosis was 
thought to be a lipid-driven disease, as cholesterol was observed in the plaques67. 
However, the presence of inflammatory cells in the lesion led to the hypothesis that 
atherosclerosis was not only a cholesterol storage disease68. Rudolf Virchow was 
the first one to explain the role of inflammatory cells in atherogenesis66. The 
implication of inflammation in the development of atherosclerosis was recently 
demonstrated in the Canakinumab Anti-Inflammatory Thrombosis Outcome Study 
(CANTOS). The CANTOS trial is a double-blind trial including patients who already 
suffered a MI and with elevated levels of systemic inflammation (CRP> 2 mg/ml), 
despite statin therapy69. Patient groups who received 150mg of canakinumab, an 
interleukin-1 Beta (IL-1β) monoclonal antibody, on top of statin treatment and 
every three months had a significant lower risk for CVD69. However, these patients 
had higher incidence of infection and there was no significant difference in all-cause 
mortality69.  
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Atherosclerosis development 
The endothelium, the inner cellular layer of blood vessels, is an almost 
impermeable barrier between blood vessels and tissues. Upon stress (e.g. low-
shear stress, hyperglycemia or inflammation), endothelial cells (ECs) become 
dysfunctional and the barrier integrity is weakened, leading to leakage, amongst 
others70. The process of atherosclerosis begins with excessive retention of low-
density lipoprotein (LDL) in the artery’s sub-endothelial space8. LDL is in turn 
biochemically modified within the arterial wall and activates the ECs. Activated ECs 
attract and capture blood monocytes via the expression of adhesion and 
chemoattractant molecules (such as vascular cell adhesion molecules (VCAMs) and 
chemokines) in attempt to clear the modified LDL. These monocytes enter the sub-
endothelial space and differentiate into macrophages, which take up the modified 
LDL and enhance the inflammatory response71. These lipid-laden macrophages, 
called foam cells, accumulate in the lesion and undergo programmed cell-death, 
apoptosis, due to this lipid overload. One of the main functions of the macrophage 
is to clear dead cells under physiological conditions, a process called efferocytosis72. 
However, in more advanced lesions, the efferocytosis process is defective and the 
non-cleared apoptotic cells will become necrotic. Together this leads to the 
formation of the plaque necrotic core, which consists of apoptotic cell debris and 
lipids73.  
In addition, smooth muscle cells (SMCs), normally located in the medial layer of 
arteries, migrate to the intima and proliferate around the plaque in response to 
cytokines secreted by activated plaque macrophages. They form the fibrous cap by 
secreting extracellular matrix protein, such as collagen and proteoglycans74. The 
fibrous cap stabilizes the plaque and protects it from rupturing; however, as disease 
progresses, the fibrous cap becomes thinner and can ultimately rupture. Indeed, 
plaque macrophages secrete matrix metallo-proteases (MMPs) which degrade 
collagen, and subsequently the fibrous cap. Furthermore, SMCs undergo cell death 
due to the plaque inflammation and uptake of oxidized lipids and rupture-prone 
regions are often observed where there is a reduced number of SMCs and fibrosis, 
accompanied by an increased number of macrophages.  
Immune cells in atherosclerosis  
Next to macrophages, SMCs and ECs, plaques contain a broad range of immune cell 
types, which are involved in the initiation and progression of atherosclerosis, such 
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as neutrophils, dendritic cells and lymphocytes75. The onset of the disease is 
characterized by stimulation/activation of the innate immune system, which is 
subsequently followed by adaptive immune responses. The innate immune system 
is the first line of defense against pathogens such as viruses and bacteria. It acts 
rapidly and is non-specific. Micro-organisms express pathogen associated 
molecular pattern (PAMPs), which are recognized by surface receptors on innate 
immune cells (e.g. macrophages, neutrophils and dendritic cells) and engulfed. 
However, the innate immune system is not always able to eliminate the pathogens 
and, in that case, the adaptive immune response is activated. The adaptive immune 
response is slower but target-specific and involves antigen-presenting cells. These 
cells will activate several effector T-cell and B-cell types. In turn, the effector cells 
will produce specific “antigen receptors” or antigen specific antibodies, to clear the 
pathogens. 
In atherosclerosis, both the innate and the adaptive immune responses play pivotal 
roles. Next to macrophages, other innate immune cell types are recruited to the 
atherosclerotic lesion, including neutrophils and dendritic cells76. Neutrophils 
accumulate in the lesions and their number positively correlates to plaque size77,78. 
They have been described to produce Neutrophil Extracellular Traps (NETs) to 
prime macrophages to produce inflammatory cytokines, resulting in increased 
atherogenesis79. Dendritic cells, on the other hand, act as bridge between the 
innate and the adaptive immune response by presenting antigens to adaptive 
immune cells. In healthy tissues, DCs are found in atherosclerotic-prone lesions and 
their number increases during the development and progression of the disease80. 
Furthermore, in advanced lesions, DCs localize to rupture-prone regions81.  
Similarly, T and B lymphocytes, as part of the adaptive immune response, have been 
observed in the plaque82. There are different kind of T-cell and B-cell subsets and 
this is reflected in their respective role during atherosclerosis. Indeed, the high 
heterogeneity of T- and B- cells allows them to have both pro- and anti-atherogenic 
phenotypes83.  
Furthermore, mast cells are also found in atherosclerotic plaques84,85. In vivo studies 
have shown that activation of mast cells led to an exacerbation of atherosclerosis 
formation and, inversely, inhibition of mast cells activation showed a reduction of 
atherosclerosis formation85.  
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Lastly, Natural Killer (NK) and NK T cells have also been implicated in 
atherosclerosis. NK cells are mostly observed in unstable plaque, where they have 
been shown to induce apoptosis and hence associate with plaque progression and 
rupture86. In addition, NKT cells also show a pro-atherogenic function, as mice 
lacking NKT type I and type II cells have a reduction in atherosclerotic plaque 
formation87.  
Macrophages in acute myocardial infarction, and post-infarct repair 
Aside from their important role in atherosclerosis, macrophages are also 
instrumental to another aspect of cardiovascular inflammation: post myocardial 
infarction repair. Following MI, cardiac remodelling takes place and can be divided 
into two phases, including an acute inflammatory reaction, followed by fibrosis and 
scar formation88,89. Both processes of the disease are tightly regulated by 
macrophages. In response to MI, monocytes infiltrate the myocardium, where they 
differentiate into macrophages and closely collaborate with cardiac resident 
macrophages to regulate cardiac repair90. In the early post-infarct phase, cardiac 
macrophages were observed to influence the pro-inflammatory response, by 
releasing a broad range of pro-inflammatory cytokines, such as IL-6 and TNF-α91. 
Contrarily, in the later post-infarct phases, cardiac macrophages were shown to 
enter a pro-repair phase, exhibiting increased phagocytic and proliferative capacity 
and this was further followed by a scar formation phenotype, where macrophages 
increased their expression of extracellular matrix remodelling genes88.  
Macrophages heterogeneity  
As mentioned previously, macrophages are the most abundant cell type in 
atherosclerosis and play a central role in ischemia-reperfusion injury and healing in 
the heart. Currently, macrophages are divided into  two main species: tissue 
resident macrophages, which are primarily of embryonic origin, and inflammatory 
macrophages, which are derived from blood monocytes and recruited to sites of 
inflammation/infection92,93. All macrophages share one important characteristic: 
they are extremely plastic and adapt extraordinarily well to their micro-
environment. This high plasticity results in multiple macrophage phenotypes 
exerting a large variety of functions94–96, such as controlling tissue homeostasis, as 
well as driving inflammatory processes, including phagocytosis, apoptosis, etc94,97.  
In addition, tissue-resident macrophages can exhibit tissue-maintenance functions 
General introduction and outline of the thesis | 1 
 
Page | 17  
 
such as cellular debris clearance or immune surveillance, generally upon instruction 
by their microenvironments92,94,96,98.  
Over the last years, extensive research has been conducted to understand how 
macrophages respond to various stimuli. It was first believed that macrophages can 
polarize into two main phenotypes, M1 or the pro-inflammatory subtype and M2 
or the anti-inflammatory subtype. However, recent evidence suggests that this 
M1/M2 paradigm is an oversimplification of macrophage polarization99. Indeed, the 
M1/M2 scheme is now seen as the two extremes of a multi-dimensional 
macrophage polarization spectrum100. Inflammatory stimuli, such as interferon-γ 
(IFNγ) or lipopolysaccharide (LPS), can induce a pro-inflammatory response in 
macrophages (classically activated/M1-macrophages), resulting in production and 
secretion of pro-inflammatory cytokines, such as IL-1β IL-6, IL-12 or tumour 
necrosis factor (TNF). On the other hand, cytokines such as interleukin-4 (IL-4) or 
IL-13 will polarize macrophages towards an anti-inflammatory phenotype 
(alternatively activated-/ M2-macrophages) and the macrophages will, in turn, 
produce anti-inflammatory molecules, such as IL-10101.  
Macrophage transcriptional plasticity has been widely studied; however, the 
functional implications of macrophage heterogeneity have been barely touched 
upon. Several key questions remain unanswered. To mention a few: (1) Do 
macrophages have distinct functions depending on the mode of activation? (2) Do 
they sense and respond differently to the surrounding micro-environment in 
disease and is this reflected by their functions? (3) Is the transcriptional plasticity 
of the macrophages mirrored by their functional phenotype? and (4) Can we build 
a functional map of macrophage plasticity that could serve as reference to interpret 
macrophages functional profile?  
Using recent technological advances, it is now possible to study the macrophage 
heterogeneity at the functional level. The next section will discuss how high content 
analysis can help in understanding macrophage functions in atherosclerosis and 
CVD risk assessment.  
High content analysis of cell function 
The term high-content analysis (HCA) defines a technique used to image and 
measure complex cellular activity. It combines automated microscopy with 
advanced analytic tools to extract multi-parametric data of single cells. HCA is based 
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on fluorescent microscopy; generally, fluorescent probes are added to cells in 
culture and subsequent biological activity can be measured102. HCA technology 
provides multiple advantages over conventional functional screening. The latter 
were generally done in single tube format, and hence were labour intensive, slow 
and required large volumes of cell culture medium. Furthermore, the data analysis 
using HCA technologies allows rapid extraction of numerous features at the single-
cell level. HCA makes it possible to simultaneously screen numerous variables in a 
semi-high throughput manner, at up to 384 (or even 1536) well plate format. 
Moreover, need for cell culture media, probes, cells and compounds/stimuli are 
therefore minimized, and thus costs. Also, all live measurements over time will not 
only give quantitative, but also spatiotemporal information, often not considered 
in functional analysis.  
Over the last years, HCA technology has evolved, and imaging software solutions 
and microscopes nowadays enable automation and contain a robotic system. The 
development of easy-to-use image analysis tools have allowed scientists to extract 
a high number of features. HCA workflow is typically composed of the following 
standardized steps: (1) (Un)stimulated cells are stained for a special functional 
phenotype, the 96/384-well format plate is then placed in an automated 
fluorescent microscope that will measure in each well the exact same parameters, 
without changing the settings. (2) Once the acquiring is done, the data analysis 
starts. (3) Images are transferred in an image analysis tool, where each picture 
containing thousands of cells will be segmented. Digital segmentation algorithms 
detect and locate each cell or sub-cellular component and turn them into one single 
digital data point. (4) Following segmentation, interesting features are extracted. 
Features range from fluorescent signal intensity or percentage of positive cells, to 
shape/morphology of the signal.  
HCA usually generates large data files of extracted features and the files are 
subsequently analysed using machine learning. Unsupervised and supervised 
machine learning help to extract phenotypic appreciations that were not 
necessarily referring to the first experimental question. Furthermore, machine 
learning algorithms help at integrating HCA data with other kind of data, such as 
phenotypic, proteomics or transcriptomics data, to build in silico models of cellular 
functions (Figure 1).  
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Figure 1. Standardized HCA pipeline 
Fluorescent functional assays are performed on (un)stimulated cells, which are imaged with 
an automated microscope. Each cell will become an individual data point during the cell 
segmentation step. Data will be extracted using powerful computational software solutions. 
Relevant information will be analysed, represented and integrated to other types of data 
sets.  
HCA was first developed in the 1980s by Pfizer for a drug screening purpose, 
generating new antibiotics103. Nowadays, it is not only used for high-throughput 
drug screening purpose, but also to image and analyse, in an unbiased way, general 
or specific cellular functions. In the past 15 years, biomedical research has 
increasingly embraced the use of HCA technologies and several genomic studies 
made use of HCA, where thousands of genes were knocked-out (KO) in a specific 
cell type and the subsequent morphological changes were analysed104. In 2005, 
Ohya et al. studied the yeast morphological phenotypes of 4,718 KO genes and 
were able to identify 2,378 candidate genes showing morphological differences in 
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at least one of the 254 parameters measured105. In the years that followed, HCA 
technologies were further applied to study the link between genes and functional 
profiles in several cell types and to build genomic atlases for a variety of functions, 
such as cell division106, cell migration107, or endocytosis108. More recently, 
technological advances in cell culture and imaging methods enabled us to study 
three-dimensional (3D) structures, also known as organoids, using HCA. Organoids 
are made of stem cells, organ progenitor cells or tissue derived cell suspensions 
grown with extracellular matrix material. By enabling cell-cell interaction, spatial 
organization of cells, organ-like functional diversity, they mimic the in vivo situation 
better than classical 2D cell monolayers109 and have been commonly used in HCA 
cancer research110–112. Furthermore, HCA can be combined with confocal 
microscopy to provide a better resolution and image contrast during 2D/3D 
screening. Altogether, HCA technologies are great tools to accurately study cellular 
functions at single cell level. The next section will define the specific aim and 
hypothesis of this thesis and will explain how we plan to use HCA techniques to 
study macrophage functions in the context of atherosclerosis and AMI repair.  
Aim and hypothesis of this thesis  
Summarizing the above, macrophages are the most abundant cell type in 
atherosclerotic plaque and are implicated in its development at all stages of 
disease. Furthermore, they play a pivotal role in AMI repair. They are well known 
to be transcriptionally and phenotypically plastic and will respond profoundly to 
their (micro-)environment. In this thesis, we aim to build a functional map of 
macrophages by using a high content analysis system in vitro to study macrophage 
functions in CVD inflammation, including atherosclerosis, acute myocardial 
infarction and cardiometabolic disorders. This map could help to understand the 
role of macrophage in health and disease. 
We hypothesize that macrophage transcriptional plasticity is reflected in their 
functional profile and that macrophages can sense their micro-environment and 
respond accordingly.  
To test this, we will: 
(1) Build a high content analyser platform (the MacroScreen platform) using 
human primary macrophages to define a macrophage functional profile 
map in vitro (chapter 2) 
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(2) Use the platform to analyse the response of macrophages to a 
cardiovascular disease environment, using two cohorts of acute myocardial 
infarction (chapter 3) 
(3) Validate the platform in a mouse study focusing on apoptosis and 
atherosclerosis (chapter 4) 
(4) Use the platform to study the effect of newly discovered biomarkers 
(bioactive lipids) for the development of obesity-related CVD (chapter 5).  
Outline of the thesis 
Macrophages are the most abundant cell type in atherosclerosis. Their 
transcriptional heterogeneity has been widely studied; however, a systematic study 
of their phenotypical plasticity is lacking. In chapter 2, we set out to build a 
“functionomics” platform (the MacroScreen), enabling us to detect several 
macrophage functions relevant for atherosclerosis and to generate a function-
based atlas of human monocyte derived macrophage responses to a variety of 
established stimuli in vitro.  
This functional map served as reference for a subsequent study, where we mapped 
the functional impact of the systemic status of patients that suffered an acute 
myocardial infarction (AMI), on human monocyte derived macrophages. Such study 
could be particularly relevant as macrophages are key players not only in 
atherosclerosis but also in AMI repair90,113, and disease compromised functions may 
thus have direct implications for disease prognosis after infarct. Chapter 3 
investigates whether our functionomics platform can pick up any functional 
changes in macrophages exposed to the serum environment of AMI patients, 
whether these functional changes are reflected in their transcriptional profile, and 
if specific functional or transcriptional patterns are associated with a poor 
prognosis.   
Chapter 4 describes the use of the MacroScreen platform for dissection of causal 
mechanisms in mouse studies of atherosclerosis. Macrophage apoptosis is an 
important process during atherosclerosis at all stages of the disease but this process 
can be beneficial or detrimental, depending on plaque stage114,115. In this HCA 
valorization study, we investigated the effects of a key regulator of myeloid 
apoptosis, the anti-apoptotic protein Mcl-1, on macrophage functions, including 
apoptosis, underpinning the benefits of the HCA platform for mechanistic in vitro 
studies.  
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In chapter 5 the MacroScreen platform is deployed in a different setting. As 
described in the introduction, obesity is associated with CVD events, however not 
all obese individuals will develop CVD overtime. Conventional classifiers for CVD 
risk lack precision, and are generally not accurate at all within the obese population, 
thus more predictive biomarkers to stratify the obese individuals are eagerly 
awaited. In this chapter, we explored lipids for their potential to predict CVD risk in 
the obese population. After the discovery of novel biomarkers, we studied their 
causal relationship with macrophage function using our functionomics platform.  
A general discussion of the main findings of this thesis is presented in chapter 6, 
also including future perspective and applications of our functionomics platform. 
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Abstract 
The anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) plays an important role 
in survival and differentiation of leukocytes, more specifically of neutrophils. Here, 
we investigated the impact of myeloid Mcl-1 deletion in atherosclerosis. Western 
type diet fed LDL receptor-deficient mice were transplanted with either wild-type 
(WT) or LysMCre Mcl-1fl/fl (Mcl-1-/-) bone marrow. Mcl-1 myeloid deletion resulted 
in enhanced apoptosis and lipid accumulation in atherosclerotic plaques. In vitro, 
Mcl-1 deficient macrophages also showed increased lipid accumulation, resulting 
in increased sensitivity to lipid-induced cell death. However, plaque size, necrotic 
core and macrophage content were similar in Mcl-1-/- compared to WT mice, most 
likely due to decreased circulating and plaque-residing neutrophils. Interestingly, 
Mcl1-/- peritoneal foam cells formed up to 45% more multinucleated giant cells 
(MGCs) in vitro compared to WT, which concurred with an increased MGC presence 
in atherosclerotic lesions of Mcl1-/- mice. Moreover, analysis of human unstable 
atherosclerotic lesions also revealed a significant inverse correlation between MGC 
lesion content and Mcl-1 gene expression, coinciding with the mouse data. Taken 
together, these findings suggest that myeloid Mcl-1 deletion leads to a more 
apoptotic, lipid and MGC-enriched phenotype. These potentially pro-atherogenic 
effects are however counteracted by neutropenia in circulation and plaque. 
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Introduction 
Antiapoptotic Mcl-1 is a member of the apoptosis regulating Bcl-2 family1. It directly 
interacts with pro-apoptotic BH3-only proteins Bim and Bid and multidomain 
proapoptotic Bad2–4, thereby inhibiting apoptosis. Mcl-1 is expressed in various 
tissues including hematopoietic cells5, in which its overexpression delays cell death 
in response to various stimuli6. Indeed Mcl-1 is critical for neutrophil survival7–10 at 
all differentiation stages11. Survival of macrophages lacking Mcl-1 does not seem to 
be impacted9, albeit that Mcl-1 deficient macrophages were observed to be more 
sensitive to apoptosis induced either by phagocytosis10, or infection12.  
While monocytes and macrophages have been the subject of extensive studies in 
the atherosclerosis field for years13, neutrophils were only more recently 
investigated due to their scarce presence in atherosclerotic plaque. Nevertheless, 
it is now believed that neutrophils are instrumental in plaque development and 
later destabilization, as we and others have shown14–16. Warnatch et al. 
demonstrated that Neutrophil Extracellular Traps (NETs) prime macrophages to 
produce inflammatory cytokines, resulting in increased atherogenesis17. Dissection 
of the contribution of neutrophils to atherosclerotic plaque progression has 
however remained difficult, since other cell populations are also affected when 
neutrophils are experimentally manipulated. Deletion of Interferon Regulatory 
Factor 8 (IRF8) for example results in neutrophilia which exacerbates 
atherosclerosis in IRF8-/- ApoE-/- chimeric mice, but was at the same time 
accompanied by changes in monocytes and several dendritic cell populations18,19. 
In addition, neutrophils have thus far not been depleted during the complete 
course of atherosclerosis. Neutrophil depleting antibodies such as the anti–
polymorphonuclear leukocyte (PMN) antibody cannot be sustained for more than 
4 weeks in mice without affecting monocyte counts16.  
As Mcl-1 is vital for neutrophil survival, whilst presumably having mild effects on 
macrophage apoptosis, we hypothesized that myeloid Mcl-1 deletion could serve 
as an efficient neutropenia model during the full pathogenesis of atherosclerosis. 
Moreover, although several Bcl-2 family members have been investigated in the 
context of atherosclerosis20–23, the role of Mcl-1 in disease progression has not been 
assessed thus far. To this end, we studied effects of specific deletion of Mcl-1 in the 
lysozyme M expressing myeloid subsets neutrophils and macrophages on early and 
advanced atherosclerosis using bone marrow transplantation of Mcl-1fl/fl LysMCre 
or wild-type (WT) bone marrow into low density lipoprotein receptor-null (LDLr-/-) 
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mice. Our study shows that myeloid Mcl-1 deletion indeed has a profound impact 
on neutrophil survival. However, Mcl-1 deficient macrophages were seen to 
accumulate more lipids in vitro and in vivo and were subsequently more sensitive 
to apoptosis. Moreover, we show that Mcl-1 is implicated in the fusion of 
macrophages. These combined effects however counteracted each other affecting 
only viable cell plaque composition, but not plaque growth. 
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Material and methods 
Animals 
All animal work was approved by animal regulatory authority of Leiden University 
and performed in compliance with Dutch national guidelines. Low density 
lipoprotein receptor-null (LDLr-/-) mice were obtained from the local animal 
breeding facility. Mcl-1fl/fl LysMcre mice were obtained from the Department of 
Immunology, Duke University Medical Center, USA and were backcrossed to 
C57BL/6J. 
Mcl-1 gene expression during atherogenesis 
Twenty male LDLr-/- mice were fed a Western-type diet (WTD) two weeks prior to 
surgery and throughout the experiment. Atherosclerotic carotid artery lesions were 
induced by perivascular collar placement24. Carotid Mcl-1 gene expression was 
analysed prior to and two, four, six and eight weeks after collar placement (n=4, per 
timepoint). The mice were anaesthetized and perfused with phosphate buffered 
saline (PBS) after which both common carotid arteries were isolated. After 
dissection of the adventitia, plaque containing segments were excised based on 
macroscopic examination, snapfrozen and stored at -80°c. Two to three 
atherosclerotic plaques were pooled per sample and total RNA was isolated using 
Trizol reagent (Invitrogen). Gene expression was analysed by real time PCR (qPCR) 
using ABI PRISM 7700 Sequence Detector (Applied Biosystems) with SYBR-Green 
technology. Mcl-1 and housekeeping gene Hprt primers used are listed in 
supplementary table 1. 
Mcl-1 gene expression in different cell types 
Murine 3T3 fibroblasts, smooth muscle cells (SMCs), cardiac endothelial cells 
(MCECs), and BMDMs stimulated with either lipopolysaccharide (10 ng/ml) and 
Interferon-γ (IFN-γ, 100 U/ml) (M1 macrophage) or Interleukin-4 (IL-4, 20 ng/ml) 
(M2 macrophage) were cultured. Total RNA was extracted and gene expression was 
analysed by qPCR. Mcl-1 and housekeeping gene 18S primers used are listed in 
supplementary table 1.  
Bone marrow transplantation and atherosclerosis induction 
Male recipient LDLr-/- mice were housed in sterile ventilated cages with food (RM3, 
Special Diet Services) and water ad libitum. Antibiotics (83 mg/l ciprofloxacin, 67 
mg/l Polymixin B and 5 g/l sugar) were supplied in the drinking water. Mice were 
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exposed to a single dose of 9 Gy total body irradiation (0.19Gy/min, 200 kV, 4 mA) 
using an Andrex Smart 225 Röntgen source (YXLON International) one day before 
transplantation. Bone marrow was extracted from femur and tibia of male Mcl-1fl/fl 
LysMcre (hereafter Mcl-1-/-) donors and wild type (WT) littermates. Irradiated LDLr-
/- mice received 2.5 x 106 BM cells of either Mcl-1-/- (n=17) or WT (n=15) via tail vein 
injection. After a recovery period of eight weeks mice were put on a WTD 
containing 0.25% cholesterol and 15% cacao butter (Diet W, Special Diet Services) 
for an additional five (plaque initiation) or ten weeks (advanced plaque). 
Blood cell analysis and flow cytometry 
Blood samples were taken by tail bleeding immediately before BMT, prior to (week 
0) and after four weeks of WTD feeding (week 4) and at the time of sacrifice (week 
5 or week 10). Peritoneal leukocytes were isolated at the time of sacrifice by 
peritoneal lavage with 10 ml PBS. Whole blood and peritoneal lavage samples were 
analysed using a Sysmex blood cell analyser (XT-2000i). For flow cytometry, white 
blood cells (WBC) and peritoneal leukocytes were stained with fluorescently 
labelled antibodies against F4/80, CD19, CD4, CD71 and CD11b (eBioscience) and 
Gr1, CD8 and CXCR4 (BD Pharmingen). Fluorescence-activated cell sorting (FACS) 
analysis was performed on a FACSCalibur with CellQuest software (BD Biosciences). 
Tissue harvesting and analysis 
Two hours before sacrifice, Mcl-1-/- or WT mice (n=5) received intraperitoneal 
injections of CXCL1 (200 ng/ml in 1 ml PBS) or PBS control. The mice were 
anesthetized and perfused with PBS. Cryosections of the aortic root tissue were 
stained with hematoxylin and eosin (HE) or Oil Red O (ORO). Lesion size was 
quantified using a Leica DMRE microscope with camera and Leica Qwin Imaging 
software (Leica Ltd). MGCs were defined as macrophages with two or more round 
nuclei on the HE slides and quantified by an animal pathologist. 
Immunohistochemical stainings were performed for macrophage (MOMA-2, 
Sigma) and vSMC (α-smooth muscle actin, Sigma) content. Apoptotic cell content 
was quantified using terminal deoxytransferase dUTP nick-end labeling (TUNEL) kit 
(Roche Diagnostics). 
LDL and VLDL isolation and oxLDL preparation 
LDL and very low-density lipoprotein (VLDL) were isolated from human plasma by 
density gradient ultracentrifugation for 20h at 4°C25. LDL concentration was 
adjusted to 0.5 mg/ml with PBS and oxidized by incubation with 0.32 mM CuSO4 
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overnight at 37°C after which the oxidation reaction was terminated by addition of 
50 µM EDTA. OxLDL was then dialyzed against PBS containing 10 µM EDTA for 24h. 
Final oxLDL and VLDL concentration were measured using the bicinchoninic acid 
protein kit (Thermo Fisher Scientific). 
BMDMs and peritoneal macrophages 
Bone marrow cells were isolated by flushing femurs and tibia with PBS and single 
cell suspensions were obtained by passing the suspension through a 70 µm nylon 
cell strainer (BD Falcon). Bone marrow cells were differentiated into macrophages 
by culturing in RPMI-1640 medium (GIBCO Invitrogen), supplemented with 10% 
(vol/vol) heat inactivated fetal calf serum (FCS) (GIBCO, Invitrogen), glutamine (2 
mM), penicillin (100 U/ml), streptomycin (100 μg/ml) and 15% (vol/vol) L929-
conditioned medium for seven days. After differentiation, BMDMs were harvested 
with lidocaine and replated at 0.5x105 cells/well in a 96 well imaging plate (BD 
#353219, Corning Life Sciences) for apoptosis, lipid uptake and fusion assay. 
Peritoneal leukocytes were isolated from Mcl-1-/- and WT mice following an i.p. 
injection of PBS before sacrifice. Cells were pooled from 2-3 mice per genotype and 
plated at 0.25x106 cells/well in 8 chamber culture slides or 24-well plates (BD 
Falcon) and non-adherent peritoneal macrophages were removed. 
Lipid loading of BMDMs and peritoneal macrophages  
Adherent peritoneal macrophages were stimulated with 20 µg/ml oxLDL or 50 
µg/ml VLDL for 24h, after which slides were washed with PBS and stained with ORO. 
Lipid loading was quantified as the ratio between the ORO stained area and total 
cell surface. BMDMs were loaded with 20 µg/ml oxLDL or 50 µg/ml VLDL combined 
with 5 µg/ml and 12.5 µg/ml Topfluor cholesterol (Avanti Polar Lipids) respectively 
for 2.5h (D0) and 120h (D5). Cell nuclei were stained with Hoechst (Sigma Aldrich) 
at 15 µg/ml.  
Apoptosis of peritoneal macrophages and BMDMs 
Adherent peritoneal macrophages were stimulated with 40 µg/ml oxLDL for 24h. 
The macrophages were detached with Accutase (PAA Laboratories GmbH), stained 
with FITC-labeled Annexin-V (ImmunoTools) and propidium iodide (Sigma Aldrich) 
and subsequently analysed by flow cytometry (FACSCalibur, BD Biosciences). For 
the BMDM apoptosis assay, cells were loaded with 20 µg/ml oxLDL or 50 µg/ml 
VLDL for 6h (D0) or 120h (D5) and subsequently stained with Hoechst and Oregon-
green or Alexa-647 labelled Annexin-V for 15 minutes26.  
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Fusion assay  
BMDMs were loaded with 20 µg/ml oxLDL or 50 µg/ml VLDL for either 24h (D1) or 
120h (D5). Macrophage fusion was measured by co-staining with calcein-AM 
(ThermoFisher Scientific) at 1 µg/ml and Hoechst. MGCs were defined as having 
two or more nuclei per calcein-segmented cell. 
Image analysis 
For all 96-well plate immunofluorescence assays (apoptosis, lipid loading and cell 
fusion), nine images per well were taken using the high content analyser (HCA) BD 
pathway 855 (BD Biosciences) with 10x objective and further analysed using 
Attovision and DIVA software (BD Biosciences).  
Human atherosclerotic plaque collection  
Stable and unstable human carotid atherosclerotic plaques segments (classified 
according to Virmani et al.27) were collected from the same symptomatic patient 
(n=22/23) undergoing carotid endarterectomy in Maastricht University Medical 
Centre (MUMC, The Netherlands) and Zuyderland Medical Center (Sittard, the 
Netherlands). Collection, storage, and use in the Maastricht Pathology Tissue 
Collection (MPTC) were approved by medical ethical committee (16-4-181) and in 
accordance with the “Code for Proper Secondary Use of Human Tissue in the 
Netherlands” (http://www.fmwv.nl). Atherosclerotic plaque segments were 
alternatively snap-frozen for RNA and microarray analysis, or formalin-fixed for 
paraffin-embedding.   
Human atherosclerotic plaque histology 
The human plaque sections adjacent to the snapfrozen segment were classified to 
determine plaque type according to Virmani et al.27. HE staining was used to 
quantify plaque size, lipid core size and hemorrhage. Alizarin red staining was done 
to measure the percentage of calcification.  
Human atherosclerotic plaque immunohistochemistry 
All stainings were performed on adjacent plaque sections for vascular endothelial 
marker CD31 (Dako), macrophage marker CD68 (Dako), T-cell marker CD3 (Dako) 
and MGC marker (cathepsin K28). MGCs were defined as cathepsin-K positive cells 
having two or more round nuclei. MGC were quantified in all sections and averaged 
per patient. Relative abundance of MGCs was calculated by dividing the number of 
MGCs by that of CD68 positive cells.  
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Human atherosclerotic plaque RNA extraction and transcriptomics 
RNA was isolated by Guanidium Thiocyanate lysis followed by Cesium Chloride 
gradient centrifugation, and then purified using the Nucleospin RNAII kit. 750 ng of 
biotinylated cRNA per sample was hybridized to Illumina Human Sentrix-8 V2.0 
BeadChip® and washed according to the Illumina standard procedure. Scanning was 
performed on the Illumina BeadStation 500. Raw expression data were extracted 
from the images using default settings and without normalization. 
 
Statistics  
Values are expressed as mean ± standard error of the mean (SEM). All statistical 
analyses were performed using Prism (GraphPad Software). Statistically significant 
differences (p<0.05) were evaluated using the Student’s t-test unless stated 
otherwise. Pearson correlation analysis was performed to assess the association 
between Mcl-1 gene expression or MGCs presence and clinical plaque traits.  
*p<0.05, **p<0.01 and ***p<0.001. 
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Results 
Mcl-1 deletion altered neutrophil levels and characteristics  
We first quantified Mcl-1 gene expression during atherogenesis. Mcl-1 levels in 
collar-induced carotid artery lesions of LDLr-/- mice gradually increased during lesion 
development and in particular in advanced plaques, six weeks after collar induction 
(Figure 1A). Of note, this increase was not validated at the protein level. Mcl-1 was 
mostly expressed in activated macrophages (M1- or M2-macropahges), as 
compared to other cell types (Figure 1B). Mcl-1 was also detectable in human 
atherosclerotic plaques, and its expression did not differ between stable and 
unstable plaque (Figure 1C). However, Pearson correlation analysis revealed that 
Mcl-1 expression did correlate with pathogenic plaque traits, with more traits in 
unstable plaques, suggesting an involvement in the disease process (Figure 1D). To 
verify whether Mcl-1 deletion indeed resulted in an efficient neutropenia model in 
the context of atherosclerosis, Ldlr-/- recipient mice were transplanted with 
LysMCre Mcl-1fl/fl (hereafter Mcl-1-/-) or wild type (WT) bone marrow (Figure 1E). 
Mcl-1-/- mice showed similar serum cholesterol and triglyceride levels, and body 
weight (Supplementary Figure 1A-C). 
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Figure 1. Regulation of Mcl-1 expression in atherosclerosis 
A, B and C. Mcl-1 gene expression measured by RT-qPCR. A. Vascular Mcl-1 expression 
corrected for HPRT housekeeping gene in a model of collar induced carotid artery 
atherogenesis in LDLr-/- mice. B. Mcl-1 expression corrected for 18S housekeeping gene in 
different mouse cell types. SMCs: smooth muscle cells, MCECs: mouse cardiac endothelial 
cells. C. Mcl-1 gene expression in human atherosclerotic plaques, represented by 
microarray normalized intensities. D. Heatmap showing Pearson correlation coefficient (p-
values) of Mcl-1 human plaque gene expression correlation with clinical plaque traits. 
N=22/23 (stable/unstable). E. Lethally irradiated LDLr-/- mice were reconstituted with WT or 
Mcl-1-/- bone marrow, and after 8 weeks of recovery, put on a Western Type Diet (WTD) 
containing 0.25% cholesterol for 5 weeks (n=17) or 10 weeks (n=19). All data is presented 
as mean ± SEM. *p<0.05 
Compatible with the notion that Mcl-1 is essential for neutrophil survival7, 
circulating and splenic neutrophil numbers were sharply reduced by 80% and 86%, 
respectively in Mcl-1fl/fl LysMcre mice9.  Circulating neutrophils were depressed in 
Mcl-1-/- chimeras both at baseline (82% depletion) and even more so under 
hyperlipidemic conditions (91% depletion) (Figure 2A). Likewise, neutrophil 
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content in Mcl-1-/- atherosclerotic lesions was decreased, albeit to a lower extent 
than in blood (Figure 2B and C), hinting to an enhanced adhesive capacity or faster 
turnover of residual neutrophils in circulation. Considering that an elevated 
CXCR4/CXCR2 balance is associated with regress to the bone marrow and that 
CXCR4 is an established measure of neutrophil ageing16, we examined neutrophil 
phenotype. CXCR4 expression on circulating and peritoneal residual neutrophils 
was increased (Figure 2D and E respectively), suggesting hyperactivation and 
increased SDF1 migratory capacity. Moreover, responsiveness of remaining 
neutrophils to the potent neutrophil chemokine CXCL1 was blunted, concordant 
with the reduced CXCR2 expression by pre-apoptotic neutrophils16. Peritoneal 
neutrophil influx 2h after i.p. injection of CXCL1 was prominent in WT transplanted 
mice, whereas Mcl-1-/- transplanted mice only showed a minor, non-significant, 
increase in peritoneal neutrophils (Figure 2F and G). Of note, neutrophil 
recruitment was paralleled by stromal egress of neutrophils into circulation in WT, 
but not Mcl1-/- mice (data not shown). Taken together, these results confirm Mcl-1 
as a crucial neutrophil survival factor, also under hyperlipidemic conditions, and 
demonstrate that Mcl-1 myeloid deletion can be used as a genetic tool to induce a 
long-lasting, severe neutropenia in atherosclerosis.  
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Figure 2. Mcl-1-/- chimeric mice have altered neutrophil levels and characteristics  
A. Circulating neutrophils were defined as Gr1+ and measured by flow cytometry in blood 
samples obtained from tail vein of WT and Mcl-1-/- bone marrow chimeras. B. 
Representative H&E pictures of WT and Mcl-1-/- atherosclerotic plaques (n=19). Neutrophils 
are indicated by the arrow. C. in aortic root atherosclerotic lesions of BM transplanted LDLr-
/- after 10 weeks of WTD (n=19). D. and E. CXCR4 expression in circulating and peritoneal 
neutrophils respectively assessed by flow cytometry (CXCR4 positive cells within the 
neutrophil gate of A). F. and G. Circulating and peritoneal neutrophil levels respectively 2h 
after CXCL1 injection measured by flow cytometry (CXCR4 positive cells within the 
neutrophil gate of A). Data is presented as mean ± SEM. ***p<0.001, **p<0.01 and *p<0.05.  
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Myeloid Mcl-1 deletion increased plaque apoptotic cell content but did not affect 
atherosclerotic lesion size  
Despite its profound effects on circulating neutrophils, and on plaque neutrophil 
content, myeloid Mcl-1 deletion did neither alter early nor advanced plaque area, 
necrotic core size, or plaque macrophage content as compared to controls (Figure 
3A-D). We did observe an increase in plaque apoptosis by 71% and 77% in 
atherosclerotic lesions of Mcl1-/- mice fed a WTD for 5 and 10 weeks, respectively, 
compared to WT mice (Figure 3E), suggesting that Mcl-1 not only plays an 
important role in the survival of neutrophils, but also of other myeloid plaque-
resident cells, such as plaque macrophages and foam cells.  
Figure 3. Effect of myeloid Mcl-1 deficiency on atherosclerotic lesion size and 
composition. 
A. Representative micrographs of Oil Red O stained aortic root sections in WT and Mcl1-/- 
mice after 5 and 10 weeks of WTD. B. Atherosclerotic lesion size after 5 weeks or 10 weeks 
of WTD quantified on Oil Red O staining using Leica image analysis system. C. Plaque 
necrotic core size after 10 weeks of WTD. D. Plaque macrophage content after 10 weeks of 
WTD assessed on Moma-2 positive staining. E. Plaque apoptotic cell content after 5 weeks 
or 10 weeks of WTD, measured by TUNEL staining. Data is presented as mean ± SEM. 
**p<0.01.  
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Mcl-1 myeloid deletion enhanced lipid-induced apoptosis sensitivity and lipid 
loading capacity of macrophages  
We next investigated the role of Mcl-1 in macrophages and foam cells in 
atherosclerosis, reasoning that hyperlipidemia could unleash a role for Mcl-1 in 
plaque macrophage biology, as has been described for macrophages undergoing 
infection12. Mcl-1-/- peritoneal macrophages displayed a higher level of apoptosis 
already at baseline, confirming that the hyperlipidemic environment by itself 
triggered the Mcl-1 survival program (Figure 4A). Moreover, Mcl-1-/- peritoneal 
macrophages, as well as Mcl-1-/- BMDMs (Supplementary Figure 2A and B), 
displayed an increased sensitivity towards oxLDL-induced cell death compared to 
WT macrophages (Figure 4A and B and Supplementary Figure 3A-E online). 
Interestingly, peritoneal foam cell numbers were increased by 2.5-fold in Mcl-1-/- 
compared to WT transplanted mice (Figure 4C), whereas total peritoneal 
macrophage numbers were unchanged (data not shown). This finding led us to 
examine the lipid loading capacity of peritoneal macrophages in vitro. In agreement 
with the elevated peritoneal foam cell counts in vivo, lipid accumulation in non-
stimulated Mcl-1-/- BMDMs in vitro was markedly increased (Figure 4D). Lipid 
loading in WT macrophages remained unchanged after incubation with oxLDL for 
24h but was substantially enhanced in Mcl-1-/- macrophages (Figure 4D). While 
incubation with VLDL increased lipid content in both WT and Mcl-1-/- macrophages, 
this increase was considerably higher in the latter cells (Figure 4D). In keeping with 
what is observed in peritoneal macrophages, Mcl-1-/- BMDMs also showed an 
increased lipid uptake capacity (Figure 4E). Thus, under conditions of 
hyperlipidemia Mcl-1 appears to be an active regulator of macrophage survival as 
well as of macrophage lipid loading.  
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Figure 4. Effect of Mcl-1 myeloid deletion on macrophage apoptosis and lipid loading. 
A. PS exposure of unstimulated or oxLDL (40 µg/ml) stimulated peritoneal macrophages 
measured by Annexin-V-OG staining. B. PS exposure of unstimulated or oxLDL/VLDL 
stimulated bone marrow derived macrophages (BMDMs) measured by Annexin-V-OG 
staining. C. Peritoneal foam cell presence of WT and Mcl-1-/- mice after 10 weeks of WTD 
assessed by Oil Red O staining in vitro. D. Lipid loading capacity of peritoneal macrophages 
after oxLDL (20 µg/ml) and vLDL (50 µg/ml) exposure. E. Lipid uptake capacity of BMDMs 
after oxLDL (20 µg/ml) and VLDL (50 µg/ml) incubation. Data is presented as mean ± SEM. 
***p<0.001, **p<0.01 and *p<0.05. 
 
Mcl1 deletion induces multinucleated giant cell formation  
Much to our surprise, we noticed the abundant presence of multinucleated giant 
cells (MGCs) in plaques of Mcl-1-/- transplanted animals after 10 weeks on WTD. 
Indeed, MGC content per plaque was increased by 118% in the Mcl-1-/- transplanted 
animals as compared to WT (Figure 5A and B), suggesting that Mcl-1 myeloid 
deficiency leads to the formation of MGCs. In addition, Mcl-1 myeloid deficiency 
increased MGCs formation by peritoneal macrophages in vitro both in control 
conditions and after incubation with oxLDL and VLDL (Figure 5C and D). To further 
investigate the Mcl1-dependent changes underlying MGC formation, we incubated 
WT BMDMs with IL-4 and GM-CSF, two known cytokines to induce giant cells29,30, 
and compared them to Mcl-1-/- BMDMs. While giant cell formation was unaffected 
after one week of culture (data not shown), it was significantly increased in Mcl-1-
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/- BMDMs compared to WT BMDMs at 13 days of culture (P value= 0.002, Figure 
5E). Mechanistically, the effect was partially mediated by hyperlipidemia, as oxLDL 
or VLDL increased MGC formation in BMDM-derived cells to a larger extent (Figure 
5E). Of note, after 13 days in culture, Mcl-1-/- BMDMs had partially lost their 
increased capacity of lipid uptake and subsequent lipid-induced apoptosis (Figure 
5F and G, respectively).  
Figure 5. Effect of Mcl-1 deletion on macrophage fusion 
A. Representative pictures of mouse aortic root sections stained with H&E. Multinucleated 
Giant Cells are indicated by the arrow. MGCs were quantified as cells containing two or 
more round nuclei. B. MGCs quantification in the atherosclerotic lesions of WT and Mcl1-/- 
chimeras after 10 weeks of WTD. C. Representative pictures of Oil Red O stained 
unstimulated, oxLDL or VLDL stimulated peritoneal macrophages. Multinucleated Giant 
Cells are indicated by the arrow D. Quantification of Giant Cell population in peritoneal 
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macrophages depicted in C.  E. MGC in BMDMs after 6d of culture in the presence of either 
oxLDL, VLDL or nothing. F. Lipid loading capacity of MGCs after 13d in culture. G. PS 
exposure in MGC population after 13d in culture. Data is presented as mean ± SEM. 
***p<0.001, **p<0.01 and *p<0.05 
To assess the relevance of Mcl-1-dependent MGC formation in human 
atherosclerosis, we quantified MGCs in human plaques. Cathepsin K+ 
multinucleated cells were frequently found in both stable and unstable plaques 
(Figure 6A and B).  Interestingly, their presence inversely correlated with Mcl-1 
gene expression in unstable plaque, and only in unstable lesions associated 
significantly with lesion hemorrhages and calcifications (P value= 0.044 and 0.055, 
respectively, Figure 6C and D).  Thus, our results unveil a hitherto unknown link 
between Mcl-1 and MGC formation, which is influenced by hyperlipidemia, an 
association potentially preserved in human atherosclerotic lesions as well. 
Figure 6. Presence of Multinucleated Giant Cells in human atherosclerotic plaques. 
A. Representative pictures of cathepsin K stained human unstable plaques. Multinucleated 
Giant Cells are indicated by the arrow B. MGCs are quantified as cells positive for cathepsin 
K and containing two or more round nuclei. C. Pearson correlation analysis showing 
coefficient (p-values) between MGCs presence and MCL-1 gene expression levels in human 
unstable plaque segments (n=18). D. Heatmap showing Pearson’s correlation coefficient/p-
values between the presence of MGCs and other clinical plaque traits. N=22/23 
(stable/unstable). * indicates significant correlation. 
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Discussion  
In this study, we evaluated the effects of myeloid Mcl-1 deletion and its 
accompanying neutropenia on atherosclerosis progression. In addition to extreme 
neutropenia, Mcl-1 deficiency resulted in increased macrophage apoptosis and 
lipid handling, and triggered multinucleated giant cell formation. First, we found 
that myeloid Mcl-1 deletion dramatically reduced neutrophil numbers both in 
circulation and in atherosclerotic lesions. This is in keeping with extensive data on 
the vital role of Mcl-1 in neutrophil survival9,10,31,32 which as we now demonstrated 
remains valid in a hyperlipidemic environment. On the other hand, Mcl-1 
overexpression33,34 and Bim deletion23, a pro-apoptotic Bcl-2 family member and 
Mcl-1 antagonist, do not affect circulating myeloid cell numbers, suggesting that 
physiological Mcl-1 levels are sufficient for normal cell function. Our work thus 
provides a mouse model for continuous neutropenia, an important advantage to 
models used in earlier studies addressing neutrophil contribution to atherogenesis. 
Though Zernecke et al. demonstrated that CXCR4 blockade aggravated 
atherosclerosis due to increased neutrophil recruitment to the plaque, they were 
unable to extend the neutrophil depletion beyond a 4 week period16. They did show 
that plaques of neutrophil-depleted mice were smaller and had a lower neutrophil 
and macrophage content, but did not evaluate plaque apoptosis or necrotic core 
size. Similarly so, CCL3-/- LDLr-/- bone marrow chimeras with 50% less neutrophils, 
developed smaller atherosclerotic lesions35. Consequently, we were highly 
surprised by the unaffected atherosclerotic lesion burden in neutropenic LysMCre 
Mcl-1-/- mice.  
Apparently the atheroprotective effects of Mcl-1 deletion in neutrophils in LDLr-/- 
mice are counteracted by potentially pro-atherogenic effects on other cell types 
targeted by the LysM conditional Mcl-1 deletion, we therefore examined in greater 
detail the role of Mcl-1 in atherosclerotic LysM+ monocytes and macrophages.  
Although Mcl-1 loss was previously shown to have no effect on monocyte and 
macrophage development in wild type mice9,10, Mcl-1-/- macrophages were more 
sensitive to apoptosis upon  an infection12 or phagocytic challenge10. We found that 
the apoptotic cell content in advanced aortic root lesions (10 weeks of WTD) was 
increased by 44% in mice with myeloid Mcl-1 deficiency. As neutrophils are only 
scarcely present in advanced lesions14 and most apoptotic cells were located in the 
central atheroma (data not shown), the high apoptotic cell density is likely to reflect 
dying LysM+ plaque macrophages. Our work thus identifies Mcl-1 as a major survival 
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protein in atherosclerotic lesions. Atherosclerotic lesion burden was however 
unaltered in Mcl-1-/- BM recipients, as were necrotic core, macrophage and collagen 
content. Similar results were obtained when studying plaque initiation five weeks 
after WTD. Our results correspond with those from Thorp et al.21, who showed 
increased macrophage apoptosis, but unchanged lesion burden in Bcl-2flox-LysMCre 
ApoE-/- mice that are deficient in macrophage and neutrophil Bcl-221. In turn, 
hematopoietic Bim deficiency, a pro-apoptotic Bcl-2-family member, had no impact 
on macrophage apoptosis and lesion burden in LDLr-/- mice23. Thus, Mcl-1-/- deletion 
in macrophages led to higher apoptosis level in advanced plaques, however it is 
clear from the above that this not always translates into a pro-atherogenic plaque 
progression.  
In addition to an increased sensitivity to oxLDL induced cell death, Mcl-1-/- 
macrophages showed augmented lipid accumulation after incubation with oxLDL 
and VLDL. In keeping, we observed elevated foam cell levels in vivo in the peritoneal 
cavity of Mcl-1-/- BM compared to WT BM recipients. These findings seem to 
contrast with those of Halvorsen et al.36, who reported reduced IL-10 induced oxLDL 
loading by THP-1 macrophages in vitro after siRNA mediated silencing of Mcl-1 and 
Bfl-1 expression. The authors did not assess effects of Mcl-1 inhibition alone, 
without IL-10 stimulation. Based on our data we hypothesize that the apoptosis-
prone phenotype of Mcl-1-/- macrophages is at least partly caused by the increased 
uptake of lipids. 
Another remarkable characteristic was the high propensity of Mcl-1-/- cells to form 
multinucleated giant cells (MGCs). MGCs, a hallmark of several chronic 
inflammatory diseases37,38, originate from monocyte-macrophage lineage and 
result from cell fusion37,39. Giao et al. have illustrated the presence of TRAP-positive 
(osteoclast like giant) cells in close relation to calcified regions and TRAP-negative 
MGCs in advanced human atherosclerotic plaques40. In addition, Samokhin et al.41 
showed that mice fed a Paigen diet displayed a 4-fold increase in MGC number in 
atherosclerotic lesions 41. In our study, we observed a higher macrophage fusion 
capacity in both Mcl-1-/- peritoneal and BMDMs, which increased even more upon 
oxLDL or VLDL stimulation. Furthermore, Mcl-1-/- deficiency in BMDMs seemed to 
promote MGC formation, independently of lipid uptake. In line with our in vitro 
findings, Mcl-1-/- atherosclerotic plaques had a 4-fold increase in MGC presence as 
compared to WT lesions. Additionally, the presence of MGCs in human unstable 
plaques correlated negatively with Mcl-1 gene expression and significantly 
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associated with hemorrhages and calcifications in the lesion. The exact role of 
MGCs in atherosclerosis is not yet fully understood, however it was previously 
shown that MGCs facilitate vascular smooth muscle cell migration in the context of 
atherosclerosis by producing cathepsin K and destroying the elastin fibers41. 
Although not providing conclusive evidence, our findings support such pro-
atherogenic role of MGCs. To our knowledge, we are the first to implicate Mcl-1 in 
the fusion of macrophages. Possibly, this is related to increased oxidative 
phosphorylation capacity for energy production in Mcl-1-/- deficient BMDMs (data 
not shown), however the exact mechanism by which Mcl-1 induces MGC formation 
remains to be investigated. 
In summary, myeloid Mcl-1 deficiency led to a profound and sustained neutropenia 
in hyperlipidemic LDLr-/- mice accompanied by enhanced oxLDL induced 
macrophage death in vitro, as well as increased atherosclerotic lesion apoptosis. 
Furthermore, Mcl-1 deficiency was shown to enhance lipid uptake and induce the 
formation of MGCs in vitro and in vivo. In line with the observation in mice, Mcl-1 
gene expression negatively correlated with the presence of MGCs in human 
unstable plaque. Taken together, the markedly lower neutrophil numbers mask the 
combined effects of a more lipid rich and apoptotic plaque in myeloid Mcl-1 
deficient animals, and result in an unchanged lesion development and progression. 
Our results clearly identify Mcl-1 as a macrophage survival protein under 
hyperlipidemia and uncover a hitherto unknown role for Mcl-1 in MGC formation. 
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Supplemental data  
 
Supplementary Table 1: Primer sequences 
  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Mcl-1 AAGAGGCTGGGATGGGTTTGT AGTCCCCTATTGCACTCACAAG 
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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Supplementary Figure 1. Lipid levels and total body weight of Mcl-1-/- chimeras are 
unchanged. 
 A. Serum total cholesterol levels at 0, 2 and 5 weeks after WTD. B. Serum triglyceride levels 
at 0, 2 and 5 weeks after WTD.  Total body weight of WT and Mcl-1-/- chimeras. Data is 
presented as mean ± SEM. *p<0.05 
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Supplementary Figure 2: Mcl-1 gene knock-out confirmation by qPCR.  
Mcl-1 gene expression in BMDMs from Mcl-1-/- mice is almost blunted as compared to that 
of WT BMDM at day 7d (A) or 12d (B) of culturing. Data is presented as mean ± SEM. 
*p<0.05; **p<0.01. 
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Supplementary Figure 3: Lipid induced-apoptosis in Mcl-1-/- BMDMs.  
A. WT and B. Mcl-1-/- BMDMs were incubated for 2,5h with fluorescently-labeled oxLDL 
(bodipy, 20 µg/ml) and subsequently stained for PS exposure using Alexa-647 labelled 
Annexin-A5 and cell associated fluorescence was measured by using a fluorescent 
microscope (BD pathway 855; representative image at 10X magnification). C. and D. show 
representative analysis performed with the DIVA software and E. represents the 
quantification. Data is presented as mean ± SEM. *p<0.05 
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Main findings of this thesis  
Macrophages are the most abundant immune cell type in atherosclerosis and their 
transcriptional plasticity has been widely demonstrated1. However, a clear link 
between transcriptional heterogeneity and the corresponding functional activity 
was lacking. Therefore, in this thesis we aimed at building a macrophage functional 
map using a high content analysis system in vitro to study macrophage functions in 
CVD inflammation, including atherosclerosis, acute myocardial infarction repair and 
cardiometabolic disorders, and link it to specific transcriptional profiles.  
In this chapter, we will discuss the following main findings and deliverables of this 
thesis: 
(1) The successful development of a ready-to-use “functionomics” platform 
(called the MacroScreen). This platform is able to measure 19 distinct 
functions of human and mouse macrophages in a semi-automated manner 
and at microscale (chapter 2 to 5).  
 
(2) The identification of a macrophage functional activation map. 
Macrophages transcriptional plasticity, which cannot be fully captured by 
the M1/M2 dichotomy, has direct repercussion on their functional profile 
(chapter 2). 
 
(3) The functional responses of macrophages to their environment. Systemic 
changes following acute myocardial infarction (AMI) reprograms human 
macrophages by dysregulating their functional and transcriptional profile. 
Furthermore, these transcriptional and functional changes correlate with 
clinical progression of the patients (chapter 3). 
 
(4) The discovery of a highly predictive lipid-signature for the development of 
obesity-related CVD. These lipids not only predict future CVD events but 
also seem causally implicated in the pathophysiology of atherosclerosis and 
related CVD, as assessed by our functionomics platform. (chapter 5). 
 
In the following, integrative discussion, we will (1) address the use of macrophages 
as sensors for CVD inflammation and discuss relevant macrophage functions in 
CVD, macrophage plasticity and the impact of macrophage source that can be used 
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in the MacroScreen; (2) compare the MacroScreen to  other currently available 
humanized platforms; and (3) focus on patient systemic environment and its 
relation to CVD.  
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The MacroScreen: a novel tool to study innate immune responses in 
cardiovascular diseases 
The use of macrophages as sensors in the MacroScreen: Macrophage functions in 
CVD and their measurement in the MacroScreen 
In chapters 2-5, we used human macrophages to assess changes in cellular function 
associated with cardiovascular inflammation, including atherosclerosis (chapter 4), 
repair after acute myocardial infarction (AMI, chapter 4), and cardiometabolic 
diseases (chapter 5). Macrophages are innate immune cells implicated in 
atherosclerosis and AMI repair. First, in atherosclerosis, macrophages are the most 
abundant immune cells and are involved at all stages of the disease. They derive 
from blood monocytes that are recruited to the vascular wall where they 
differentiate into macrophages and ingest oxidized low-density lipoprotein (oxLDL) 
to become lipid-laden foam cells, forming the atherosclerotic plaque. Second, after 
an AMI event, macrophages are recruited to the ischemic heart and contribute to 
cardiac repair by regulating, amongst others, inflammation, apoptosis and 
extracellular matrix  degradation and formation, and angiogenesis2. In chapter 2, 
we describe the development of a high content analysis platform able to measure 
19 distinct macrophage functions, all relevant for the development of 
atherosclerosis, associated inflammatory responses, and AMI post injury repair. 
This platform allows us to understand how certain environmental cues (chapter 2 
and 5) or systemic patient environment (chapter 3) can affect macrophage 
functional profile and subsequently relate to CVD incidence.  
In the next paragraphs, we will further discuss the implication of each function 
included in the MacroScreen in the context of atherosclerosis and AMI repair. 
Furthermore, we will discuss possible other functions the platform could cover.  
Cholesterol metabolism 
Cholesterol metabolism in macrophages is an important player during 
atherosclerosis, it involves excessive uptake of modified cholesterol and reduced 
reverse transport of cholesterol to HDL particles3,4. Studies in mice have shown that 
inhibition of lipid uptake by depletion of certain scavenger receptors results in a 
reduction of atherosclerotic plaque development. Babaev et al. showed that 
deletion of myeloid class A scavenger receptors in mice reduced the atherosclerotic 
lesion area by 60%5. A similar reduction in lesion area (76.5%) was observed after 
depletion of CD36, a class B scavenger receptor, and this was attributed to reduced 
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foam cell formation by 60%6. Additionally, increased reverse cholesterol transport, 
called cholesterol efflux, from macrophages has also shown beneficial effects on 
atherosclerosis. Stimulation of liver X receptor α (LXRα) in macrophages leads to 
upregulation of ATP binding cassette A1 (ABCA1), a cholesterol transporter, and 
was seen to reduce atherosclerotic lesions7–9, confirming that regulation of 
cholesterol metabolism in macrophages is crucial in atherosclerosis. Unsaturated 
fatty acid, such as palmitic and linoleic acid (included in chapter 2) can 
downregulate ABCA1 and ABCG1 expression, via inhibition of agonist binding to 
LXRα10. Furthermore, the pro-inflammatory micro-environment of the 
atherosclerotic plaque is also able to regulate foam cell formation, as interleukin-
12 (IL-12) and IL-18 were shown to reduce ABCA1 expression, and thus cholesterol 
efflux by macrophages11.  
Mitochondrial functions 
During the process of foam cell formation, free cholesterol can disrupt 
mitochondrial functions in macrophages12. Mitochondria are cell organelles 
exerting a myriad of functions essential for cell homeostasis, including regulation 
of ATP production, reactive oxygen species (ROS) production or apoptosis signal13 
and macrophage mitochondrial dysfunction has been associated with inflammation 
in cardiovascular disease. Yu et al. observed a reduction in mitochondrial oxygen 
consumption and mitochondrial DNA (mtDNA) copies in human atherosclerotic 
necrotic cores and fibrous cap. This observation was also made in ApoE-/- mice fed 
a high-fat diet and increasing mitochondrial respiration by restoring  mtDNA copy 
number through overexpression of Twinkle, a mitochondrial helicase, led to smaller 
and more stable plaques14. In the context of cardiac repair after MI, three days post 
infarct, cardiac macrophages have been observed to exhibit dysregulated 
mitochondrial function, as shown by e.g. upregulation of genes involved in 
oxidative phosphorylation, hinting to a macrophage metabolic switch15.  
ROS production 
ROS production is a critical function of macrophages. To combat infection, 
phagocytes, including macrophages, release massive amounts of reactive oxygen 
species, a process known as respiratory burst16. Macrophage-derived ROS are 
produced by mitochondria e.g. fatty acid oxidase (NOX4), in endosomes (NOX1), in 
cytosol, or at the cell membrane (e.g. via NADPH oxidases (NOX4 and 5) and 
extracellularly (myeloperoxidases etc)). Excessive intra- and extracellular ROS has 
been repeatedly linked to atherosclerosis development16,17. Xu et al. showed that 
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deletion of NOX1 and NOX2 leads to reduced ROS macrophage production and 
defective macrophage differentiation from monocytes18. Furthermore, a recent 
study showed that reduction of atherosclerotic plaque by treatment with the 
antioxidant flavonoid quercetin in ApoE-/- mice was attributable to decreased ROS 
production by macrophages19. Additionally, LDLR-/- mice irradiated and 
transplanted with mitochondrial catalase transgenic mouse bone marrow, known 
to have reduced mitochondrial oxidative stress, showed less macrophage oxidative 
stress in atherosclerotic lesions and in turn, smaller plaque size20. ROS production 
is also critical to cardiac repair following MI, as ROS was associated with the amount 
of necrosis after MI and overexpression of superoxide dismutase in mice led to 
improved cardiac function21. In addition, bone marrow derived macrophages were 
found to be the main source of increasing expression of gp91phox, also known as 
NOX2, during the first stages of cardiac repair22.   
Cytokine production 
Next to ROS production, macrophages also produce a broad range of cytokines 
during cardiovascular disease. Cytokines are effector proteins that will act as pro or 
anti-inflammatory signals and are abundantly found in atherosclerotic lesions or in 
the infarcted heart23. In atherosclerosis, cytokines are first released by 
macrophages after oxLDL uptake and this will, in turn, become a vicious circle of 
inflammation, as cytokines will further activate macrophages and other cell types 
to release more cytokines progressively. Pro-inflammatory cytokines, such as 
Interferon-γ (IFNγ) and tumor necrosis factor (TNF) have pro-atherogenic 
properties, as TNFα-deficient or IFNγ-deficient ApoE-/- mice showed reduced 
atherosclerotic plaque size, mostly attributed to less foam cell formation, 
expression of other pro-inflammatory markers24 and decreased lipid content25.  
Contrarily, anti-inflammatory cytokines, such as IL-13 or IL-10, commonly exert 
anti-atherogenic effects by modulating macrophage phenotype26 and lipid 
metabolism27, respectively. Similarly, during cardiac repair following MI, 
macrophages first release a range of pro-inflammatory cytokines, such as IL-1β and 
TNF-α, and this is followed by a switch to an anti-inflammatory state, mediated by 
anti-inflammatory cytokines, such as IL-4 and IL-1028. This switch seems beneficial, 
as treatment of mice after MI with IL-10 led to increased polarization to M2 
macrophage and improved cardiac functions, such as ejection fraction and left 
ventricular dilation29.  
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Inflammasome activation 
Another key pro-inflammatory cytokine produced by macrophages is IL-1β. IL-1β is 
the result of the macrophage inflammasome activation in response to cholesterol 
crystals and oxLDL30,31. The inflammasome is a protein complex containing one 
nucleotide-binding oligomerization domain-like receptors (NLR) protein, an 
apoptosis-associated speck-like (ASC) protein and a cysteine protease caspase-1 
and has widely been reported to play an important role in the progression of 
atherosclerosis. Indeed, in a LDLR-/- mouse model, Duewell et al. transplanted bone 
marrow lacking NLRP3, ASC or IL-1β and observed a regression in atherosclerosis 
development by 69%32. Similarly, mice lacking ASC and subjected to 
ischemia/reperfusion injury displayed smaller infarct size, and improved cardiac 
repair33. Prior to the secretion of IL-1β in macrophages, the inflammasome complex 
activates caspases, which will then turn on the programmed cell death machinery 
or apoptosis.  
Apoptosis and phagocytosis  
Apoptosis is another key process in the development of atherosclerotic lesions and 
after MI.  Macrophages have been shown to undergo apoptosis at all stages of 
atherosclerosis34,35, however, macrophage apoptosis will affect lesion progression 
distinctively depending on plaque stage34,36,37. In early mouse and human lesions, 
macrophage apoptosis is thought to protect against plaque progression, as they are 
cleared by phagocytosis, preventing the formation of a necrotic core38. In contrast 
to advanced lesions, where apoptotic cell clearance by phagocytosis is defective, 
leading to the formation of larger necrotic cores consisting mostly of lipids and 
apoptotic cell debris36,39,40. Impairing phagocytosis by depleting phagocytic 
receptors such as Mertk or Lrp1 has shown to increase apoptosis and plaque 
size41,42. Second, macrophages help at resolving the inflammation in the post-MI 
response by phagocyting apoptotic myocytes28. Impaired macrophage 
phagocytosis after MI was linked to differed inflammation resolution and disrupted 
cardiac repair43. 
Giant cell formation 
Another intriguing and less known macrophage function is the formation of giant 
cells. Multinucleated giant cells result from the fusion of macrophages and have 
only been observed in calcified regions of human atherosclerosis44. Furthermore, 
cathepsin K expressing giant cells, were previously observed in the central 
atheroma, close to the media, where they cleave elastin fibers and facilitate smooth 
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muscle cell migration. In chapter 4, we have investigated the effect of Mcl-1 
myeloid deletion in atherosclerosis and observed a great increase in giant cell 
formation. However, the exact mechanism and contribution to atherosclerosis 
remains to be elucidated.   
Other functions 
In conclusion, we built a platform able to investigate major macrophage functions 
in CVD, however macrophages exert some other key functions that are not (yet) 
included in the platform. First, macrophage foam cell formation also depends on 
cholesterol efflux. However, our platform does not yet include a cholesterol efflux 
assay and it would be important to complement our lipid uptake assay with a 
measure of reverse cholesterol transport, e.g. by micro scaling an existing efflux 
assay45. Second, human macrophages also act as antigen presenting cells and 
express major histocompatibility complex class II (MHC II), as well as Human 
Leukocyte Antigen-DR isotype on their surface to elicit an adaptive immune 
response46. Furthermore, macrophage MHC II expression can be regulated by  
autophagy, a process of self-digestion to maintain energy homeostasis and 
macrophage autophagy has been shown to be athero-protective in the later stage 
of the disease47. Therefore, measuring macrophage antigen-presentation and 
autophagy capacity could be indicative of macrophage performance in CVD. Third, 
macrophage migration to tissue is a key process in CVD. To be able to infiltrate  and 
migrate in tissue, macrophages employ focal proteolysis, secreting several 
proteases, such as matrix metalloproteinases or cathepsins48. Additionally, 
macrophage metalloproteinases also regulate the extra cellular matrix turnover 
after AMI49. Therefore, assessment of macrophage migration and proteolytic 
activity would be an important addition to the MacroScreen. Lastly, hypoxia or the 
lack of oxygen has been suggested to promote necrotic core formation in 
atherosclerosis50 and is also observed in the heart after AMI. In response to hypoxia 
macrophages, will stabilize hypoxia-inducible factor 1, and subsequently polarize to 
pro-inflammatory macrophage51. Measuring macrophage hypoxic response in the 
MacroScreen would therefore also complement the function panel. 
Capturing macrophage functional plasticity with the MacroScreen 
In chapter 2, we have shown that macrophage transcriptional plasticity is reflected 
in their functional behaviour, resulting in five functional clusters of macrophage 
activation. At first, macrophages were thought to present in two phenotypes: M1 
(pro-) and M2 (anti-inflammatory macrophages). M1 polarization is induced by pro-
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inflammatory cytokines, such as LPS and IFN-γ and hence M1 macrophages exert 
pro-inflammatory functions. On the other hand, macrophages are polarized 
towards M2 by a broad range of anti-inflammatory cytokines (e.g. IL-4, IL-13, IL-10), 
to exert tissue remodelling and wound healing functions. Over the years, 
accumulating evidence suggested that the dichotomous macrophage polarization 
model was incomplete and, depending on the activating stimulus and functional 
profile, the M1-M2 bipolar activation was further refined to include M2a, M2b, M2c 
and M2d subgroups and other subtypes (M4, Mox, Mhem and M(Hb))52,53. All these 
macrophage subtypes were observed in atherosclerotic lesions, with M1-like 
macrophages being more abundantly found in rupture-prone plaque regions or 
unstable plaque segments; whereas M2-like macrophage were found in the 
adventitia or stable plaque regions54,55. Moreover, Mhem and M(Hb) macrophages 
were associated with intraplaque haemorrhages56, whereas Mox macrophages was 
suggested to be induced by oxidised phospholipids and showed pro-atherogenic 
features57. Next to their high heterogeneity, plaque macrophages appear to be very 
plastic and are able to switch phenotypes depending on their environment58. 
Indeed, M1 and M2 macrophages can reverse their phenotype, when exposed to 
M2 and M1 stimuli, respectively59,60.  Taken altogether, this shows that 
macrophages respond differently depending on stimulus and that their polarization 
profile is complicated. Furthermore, most of the polarization studies are performed 
in vitro using at most two stimuli and this setting obviously does not reflect the 
complexity of the in vivo situation. In the infarcted heart environment, there is a 
great amount of effector molecules able to activate macrophages. Using our 
platform, we were able to study individual stimuli to identify specific activation 
pathways related to certain functions, but we also included combinations of stimuli 
(chapter 2) to reflect chronic inflammation and human diseased serum to reflect 
the systemic environment (chapter 3). This allows better in vitro mimicking of 
complex activation profiles observed in vivo.  
The use of different types of macrophages in the Macroscreen 
In our newly developed functionomics platform (chapter 2 to 5), we made use of 
monocyte-derived macrophages (MDM). However, this is not the only type of 
human macrophages. In this section, we will discuss source-dependent differences 
in makeup of macrophages, and repercussions thereof for the MacroScreen 
application.  
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Monocyte-derived vs tissue-resident macrophages  
It is nowadays widely accepted that there are two principal types of macrophages: 
tissue-resident macrophages, mainly of embryonic origin, and inflammatory 
macrophages derived from blood monocytes and recruited to the site of 
inflammation61. Tissue-resident macrophages originate from the yolk sac or fetal 
liver during embryonic development and are seeded into the respective tissues 
before birth, maintained independently of monocytes61–63. Not only do they differ 
regarding their origin, tissue-resident macrophages and recruited macrophages 
were also seen to exert different functions. Indeed, embryonic macrophages were 
shown to exert tissue remodelling and homeostatic functions, whereas MDMs 
mainly have inflammatory functions, such as pathogen killing and host defence64, 
serving as reservoir for temporary repopulation of macrophage-depleted tissue. 
Resident macrophages exert a variety of homeostatic functions under normal 
conditions, such as phagocytosis of apoptotic cells62, lipid homeostasis in the liver65 
or electric conductance in the heart66. Upon infection, but also during cardiac repair 
after AMI and chronic sterile inflammation (e.g. atherosclerosis), macrophages 
were initially thought to originate from blood born monocytes67, which after 
recruitment differentiate into (often short-lived) inflammatory macrophages. More 
recent studies suggest resident macrophage proliferation as main source of 
macrophage pool maintenance in atherosclerotic plaques68,69, and in the heart2,70. 
Accordingly, resident hematopoietic progenitor cells were shown to reside in 
murine adventitia71,72. Furthermore, proliferating macrophages were observed in 
all stages of atherosclerosis, however, this process was mostly prominent in early 
lesions where almost 50% of replicating macrophages derived from resident 
macrophage proliferation68. In addition, resident macrophage proliferation can 
affect atherosclerosis, as Gage et al. showed that increased atherosclerotic plaque 
burden after disruption of LXRα phosphorylation was attributed to lesion-resident 
macrophage proliferation. Yet, these results must be interpreted with caution, as 
recent doubts were emitted regarding that the clonal expansion of plaque 
macrophage pool might be overestimated73.  
Our in vitro functionomics platform described in chapter 2-5 is closely modelling 
inflammatory macrophages as it focuses on monocyte-derived macrophages 
isolated from healthy volunteers and differentiated for seven days using 
macrophage colony-stimulating factor (M-CSF).  
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iPSC derived macrophages to mimic tissue-resident macrophages 
One could argue that our platform does not mimic the tissue-resident macrophage 
phenotype. Isolating human tissue-resident macrophages is laborious and the 
number of isolated cells is usually limited. Furthermore, care should be taken when 
working with isolated tissue-resident macrophages, as their transcriptional profile 
is affected by the isolation procedure, as shown by Gosselin et al. with human and 
mouse microglia, the brain-resident macrophages74. One attractive alternative to 
study the tissue-resident macrophage phenotype would be the use of human 
induced pluripotent stem cells (iPSC) derived macrophages (iMacs). iMacs are 
generated in vitro with a protocol that mimics the in vivo situation in the yolk sac75. 
They have been shown to resemble human and mouse yolk sac76,77 and fetal liver78 
derived tissue-resident macrophages, especially in terms of transcription profiles. 
To program iMacs into specific tissue-resident macrophages, two approaches have 
been proposed75. First, iMacs can be cultured in the presence of effector molecules, 
such as specific cytokines. For instance, Abud et al. successfully produced brain-
resident macrophages, a.k.a. microglia cells, by exposing iMacs to CSF1, IL-34 and 
TGFβ. These iMac-derived microglia cells resembled real microglia, as they 
expressed microglia-specific genes and proteins and showed increased 
phagocytotic activity79. However, this technique lacks the complex milieu of the in 
vivo situation and cannot completely mimic real microglia75. Second, iMacs can be 
differentiated to tissue-resident macrophages by culturing them with other cell 
types in that particular tissue, such as astrocytes and neurons for microglia79 or with 
complete organoids. In the context of cardiovascular inflammation, iMacs could be 
cultured with cardiomyocytes to recapitulate cardiac-resident macrophage 
functions or with smooth muscle and endothelial cells in a lipid-rich environment 
to acquire a plaque phenotype. Alternatively, to mimic the atherosclerotic plaque 
environment, iMacs could also be cultured in plaque conditioned medium or 
lysates. However, the functional similarity between iMacs-derived tissue resident 
macrophages and tissue-resident macrophages remains to be elucidated, and this 
could be done using the MacroScreen platform.  
The use of cell lines in the MacroScreen 
Isolating human CD14+ monocytes from peripheral blood mononuclear cells 
(PBMCs) for our HCA platform is time consuming and cell yields were usually low, 
as monocytes only represent three to seven percent of the total PBMCs80. 
Furthermore, to avoid donor-to-donor variability reflected in cell phenotype, we 
always pooled five to seven donors per experiment. Another alternative to MDMs 
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to study in vitro human macrophage functional identity could be the use of 
immortalized cell lines, such as THP-1. THP-1 cells are monocyte-like cells obtained 
from acute monocytic leukemia81 with stable genetic background, making them an 
interesting tool to study macrophage functions82. However, recent comparison 
between MDMs and THP-1 cells revealed that THP-1 cells were less sensitive to LPS 
stimulation81, and that gene expression profiles do not fully correlate between THP-
1 cells and MDMs83,84. This was confirmed at the functional level, as macrophage 
surface markers were only comparable for 41%85. Therefore, using THP-1 cells to 
assess cellular functions on our functionomics platform should be tested and 
compared to MDMs functional profile before switching to cell lines.  
In conclusion, the use of MDMs in the MacroScreen does not reflect the full 
diversity of human macrophages. However, before using other cell types in the 
platform, such as cell lines to have a more controlled environment, or iMacs to 
mimic tissue-resident macrophages, these should be functionally tested and 
compared to MDMs functional signatures.  
Humanized test platforms  
The need for humanized test platforms 
Biomedical research mainly relies on animal models such as mice, which represent 
a fast and easy readout for studying, amongst others, CVD inflammation including 
atherosclerosis, myocardial infarction repair or cardiometabolic disorders. Animal 
testing was traditionally thought to be an unavoidable step in fundamental 
research and drug discovery. However, it is increasingly clear that humans are not 
an inflated, big copy of mice and most results derived from animal testing cannot 
be directly extrapolated to humans86. Indeed, Pasterkamp et al. elegantly showed 
that the main mouse immune-associated genes and pathways causally associated 
with murine atherosclerosis had no association with human atherosclerotic plaque 
traits and subsequent incidence of coronary artery disease (CAD) or stroke87. 
Furthermore, many clinical trials testing drugs have failed due to grave side effects 
or drug efficacy issues, although the tested drugs were safe and effective in animal 
models88–90. Moreover for ethical reasons, increased efforts are being made to 
reduce the number of animals used in research (applying the 3R rule; replacement, 
refinement and reduction)91. We believe that our platform could be a good 
alternative to animal testing of innate immune responses, as it is based on human 
primary macrophages and it covers the major inflammatory processes involved in 
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the pathophysiology of atherosclerosis, including phagocytosis, oxLDL uptake and 
apoptosis (chapter 2). Furthermore, as we were able to show in chapter 3, our 
platform can detect changes in blood, which are able to alter macrophage functions 
relating to poor prognosis after an acute myocardial infarction. In addition, we were 
able to discover human immune genes directly linked to infarct size, showing the 
potential of the platform to unravel new mechanistic pathways linked to 
cardiovascular disease (chapter 3).  
Goals of current humanized test platforms 
In the last two decades, the field of humanized test platforms has gained growing 
interest and many platforms are currently being developed to serve several 
purposes in a broad range of research fields92. First, humanized test platforms were 
used to identify specific genes associated with biological processes. For instance, in 
the context of atherosclerosis, Domschkle et al. discovered four novel genes 
involved in LDL uptake in monocyte-derived macrophages93. Second, humanized 
test platforms can also be used to assess complex cell phenotypic changes after 
screening a compound library and to help selecting potential drug candidates, as 
illustrated by a study of Gao et al. who screened a library of 2,600 compounds and 
measured their impact on ABCA1 expression in HepG2 cells. They identified and 
validated 10 compounds that increased ABCA1 gene expression94. Third, 
humanized test platforms can be used as disease models to study mechanistic 
pathways and discover new potential drugs, e.g. Honarnejad et al. aberrantly 
expressed a mutant causing Alzheimer’s disease in HEK293 cells to discover new 
drugs95.  
In this thesis, we developed a humanized high-throughput platform to model innate 
immune responses relevant to cardiovascular diseases with special emphasis on the 
functional behaviour of macrophages. The MacroScreen can detect, in a high-
throughput and -content manner, 19 distinct functions, in contrast to mostly 
singular parameters measured by all the platforms described above.  
Possible improvements of the MacroScreen  
In the context of CVD, measuring macrophage function in vitro does not fully 
represent the complexity of the in vivo situation, which for atherosclerotic plaque 
contains, next to macrophages, smooth muscle and endothelial cells (ECs) and T-
lymphocytes amongst others, and for myocardium, cardiomyocytes, fibroblasts and 
ECs. Therefore, it is important to stress that our platform neither covers cell-cell 
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interaction, nor cell-cytokine and cell-matrix interaction. Extracellular matrix 
components, such as proteoglycans, hyaluronic acid, and collagen deposition are 
instrumental in tissue remodelling processes in the  atherosclerotic plaque or in the 
post-ischemic heart96,97. Thus, to better mimic the complexity of the in vivo 
pathophysiology of these diseases, some improvements could be made, which will 
be discussed below.  
First, during atherogenesis, the endothelium becomes dysfunctional, leading to a 
weakened barrier integrity and leakage98. Endothelial cell dysfunction leads to the 
infiltration of blood monocyte to the vascular wall. During atherosclerosis, smooth 
muscle cells (SMCs), which under normal conditions exhibit a contractile 
phenotype, will undergo phenotypic switch to migrate from the media to the intima 
and proliferate, to produce collagen and form a fibrous cap99. Therefore, our innate 
immune platform could be complemented with EC and vSMC functional profiles, to 
create a humanized model of atherosclerosis cell functionality. Most of the 
processes included in the MacroScreen are also relevant to ECs and SMCs, such as 
apoptosis and cytokine production but some cell-specific functions should be 
added. Human SMCs from advanced atherosclerotic plaques have been shown to 
decrease proliferation and enter a state of senescence100. Furthermore, as 
explained above, during atherogenesis SMCs migrate to the intima to form a fibrous 
cap101. In addition, vSMCs can differentiate to osteoblast-like cells during the course 
of atherosclerosis and produce micro-calcification, which  are known to promote 
plaque rupture102. Therefore, phenotype, proliferation, senescence, migration and 
calcification assays are the most obvious functionalities relevant to atherosclerosis 
and should be added to our functionomics platform to complement the current 
macrophage functional profile.   
A second limitation of our platform is that all of the above described assays are 
based on two-dimensional (2D) monolayers. Three-dimensional (3D) cell cultures 
have emerged and offer a great opportunity to integrate cell-cell interaction, cell-
extra cellular matrix (ECM) interaction, tissue oxygenation and nutrient 
gradients103. Three-D cultures were initially developed by growing single cell lines 
into spheroids. This was prominently used in the cancer field, where 3D spheroid 
cultures showed a high potential for drug discovery103,104. Later on, the spheroid 
approach was slowly abandoned in favour of organoids, which offer a better 
representation of cell heterogeneity as they were directly derived from human 
tissue or stem cells. Organoids are now widely used in biomedical research to grow 
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organs such as brains105 and kidneys106, but also tumors107. Interestingly, organoids 
have also been used in the field of cardiology to study the cardiac formation during 
organogenesis108 and (congenital) cardiomyopathies109. More recently, even more 
refined multicellular organoid models have been designed such as endothelialized 
myocardium, consisting of endothelial cells bioprinted in a 3D hydrogel scaffold and 
seeded with cardiomyocytes to form a contracting myocardium110. Another 
example was established by Wimmer et al., who successfully created a human 
blood vessel organoid composed of endothelial cells, pericytes, mesenchymal 
stem-like cells and haematopoietic cells as a model of diabetic vasculopathy111. 
They showed that exposure of blood vessel organoids to high concentration of 
glucose and cytokines led to the thickening of the basement membrane, a process 
also observed in diabetic patients, proving that this 3D model was structurally and 
functionally resembling the in vivo situation. The latter example, however, does not 
consider biomechanical forces, an important aspect of vascular disease. Recent 
advances in microfluidics have enabled the development of 3D blood vessels under 
flow112. For instance, van Duinen and colleagues developed a robust high-
throughput 3D microvessel to assess barrier function under continuous flow113. 
Another recent example was brought by Poussin et al., who established a human 
3D model of endothelial microvessels under flow, able to measure leukocyte 
adhesion to the lumen114.  
Summarizing the above, the field of in vitro humanized test models for (diseased) 
vasculature and myocardium is increasingly growing to allow rapid, cheap and more 
reliable way to study atherosclerosis and AMI, respectively. The strength of the 
MacroScreen, compared to other humanized platforms, lies in the development of 
a multi-parametric platform, able to measure 19 distinct macrophage functions in 
a high-throughput way, as opposed to the measurement of a single function in 
current platforms. Our platform is a fast and cheap way to measure cell 
functionality, as compared to organoids. However, one should realize that the 
MacroScreen is an in vitro static 2D model and lacks the physiological relevance of 
the dynamic 3D in vivo situation. To mimic the complexity of the in vivo situation 
and capture the full spectrum of cellular functions involved in CVD-related innate 
immunity, co-culture of macrophages with other cell types, such as SMCs and ECs 
or deployment of cell free (artificial or tissue based) matrices to form a “3D plaque 
on a chip” and further functional analysis could be performed.  
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Patient macro-environment and CVD risk  
Systemic environment and its link to CVD risk  
Chapter 3 of this thesis highlights the potential of mapping the patient’s systemic 
environment, defined as patient circulating plasma or serum containing a variety of 
effector molecules, for disease (prognostic) diagnosis, as exposure of macrophages 
to 20% serum of AMI patients led to functional as well as transcriptional changes 
that accurately correlated with infarct size four months after the event. This is 
probably attributable to all kind of effector molecules, released/contained in 
patient serum upon such major ischemic event. Currently, patient diagnosis relies 
on a few molecules or risk factors; however, we further show in chapter 5 that 
measuring a higher number of features can lead to a great improvement of disease 
prediction. In chapter 5, we screened circulating lipids to discover new biomarkers 
for the development of obesity-related cardiovascular disease. The plasma lipid 
profiles, in particular of cholesterol ester and triglyceride content, have widely been 
shown to be predictive of cardiovascular event 115. Lipidic molecules are not the 
only systemic predictors of CVD. Atherosclerosis is, as previously explained, seen as 
an inflammatory disease and measurement of systemic inflammatory cytokines has 
showed its potential in terms of event prediction. High sensitivity C-reactive protein 
(hs-CRP) and other pro-inflammatory cytokines such as IL-6, serum amyloid A and 
soluble intercellular adhesion molecule type I and chemokines, such as chemokine 
ligand 2 or 8, have been observed as independent predictors of CVD116,117. 
Furthermore, it was recently confirmed that targeting the inflammation by treating 
high-risk patients with an IL-1β antibody reduced the risk of CVD by 15%118. Since 
then, many studies are trying to investigate the role of different cytokines, such as 
IL-5, IL-6 receptor, IFN-γ and TNFα in disease prediction119. However, these 
biomarkers assume that patient populations are all similar and that a universal 
disease mechanism exists that applies to all patients, which can be captured by one 
single biomarker. In obesity, for example, increase in BMI leads to an increase in 
the most common lipid predictors (including LDL cholesterol, total cholesterol) and 
inflammatory markers120,121. Therefore, better prediction and subclassification of 
high-risk population and subsequent therapy tailoring is needed. Our lipid 
signature, confirmed in two independent cohorts of obesity, could, in the future, 
serve as new biomarkers for obesity-related cardiovascular disease.  
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The need for precision medicine  
Obesity is a very heterogenous condition, available diagnosis tests and treatments 
for obesity-related comorbidities are not efficient in all patients. Thus, there is a 
need for more precise medicine. Precision medicine is defined as the concept of 
characterizing each patient separately to select more effective treatment. The 
recent advances in “-Omics” techniques has greatly helped to deeply characterize 
patient groups at several levels, such as genes, proteins, metabolites122. However, 
in a recent study, only 2.7% of gene loci were associated with BMI123. Furthermore, 
another genome wide association (GWAS) study showed that, in a population of 
200,000 individuals, only 10.6% of coronary artery disease (CAD) could be explained 
by genetics124. This shows the need to integrate environment-derived cues into the 
characterization of high-risk individuals. Lipidomics, as performed in chapter 5, has 
already been used before to facilitate to reclassification of high-risk patients125. For 
instance, Fan et al. performed a comparison of metabolome profile between 
distinct subtypes of CAD and identified 89 differential metabolites classifying with 
an accuracy >90% in 2,324 patients125. A common limitation to such metabolomics 
approaches is the lack of causal assessment. Demonstration of causality of a marker 
in disease will not only facilitate development of specific therapeutic approaches, 
but it also warrants that any changes in marker level will reflect changes in disease 
risk. Investigating biomarker causality in disease development and progression can 
help understand which mechanistic pathways are altered and further design robust 
treatment. In an ideal situation, novel biomarkers could serve as risk predictors but 
could also be modifiable by specific therapies and subsequently reduce disease-
risk. These risk factors could have the potential to better stratify risk population, 
where standard risk factors, such as CRP or LDL, lack precision. In this thesis 
(chapter 5), we have thoroughly assessed the implication of our lipid-signature in 
CVD development by investigating their presence in atherosclerotic plaques and 
their effect on macrophage functions using our “functionomics” platform. Further 
analyses on our predictive lipid-signature could help understand how these lipids 
dysregulate phagocytosis, how this is reflected in disease progression and how 
certain drugs could possibly reverse this phenotype to study risk reduction 
properties. In the future, biomarker research should be more centered on causality 
assessment as this allows better and more precise disease prevention.  
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Linking systemic inflammation to CVD risk using the MacroScreen: a monocyte 
centered view 
Precision medicine uses many “-omics” platforms to deeply characterize patients, 
and our functionomics platform developed in chapter 2 could help to further 
characterize patient phenotype by directly screening functionality of circulating 
monocytes after a cardiovascular event. In this thesis, we have used monocytes-
derived macrophages from healthy volunteers, but one could think of adapting the 
platform to enable monocyte screening. AMI leads to an increased production and 
release of classical monocytes from the spleen, worsening atherosclerosis and, 
subsequently, the incidence of secondary CVD events during followup118,126. 
Moreover, the systemic blood environment was demonstrated to influence 
monocytes; for example, in patients with familial hypercholesterolemia, a genetic 
disorder leading to high level of circulating LDL, monocytosis was observed127. In 
addition, dyslipidemia also activated monocytes and regulated their adhesion to 
the endothelium128. Therefore, investigating the systemic environment in terms of 
monocyte functionality and linking it to secondary event would be of great interest. 
Monocytes represent 3-8% of total circulating leukocytes and are embedded in 
plasma, the patient’s systemic environment129. Human monocytes are divided in 
three subsets based on their expression of CD14 and CD16. Classical monocytes 
(CD14++ CD16-), intermediate monocytes (CD14+ CD16+) and non-classical 
monocytes (CD14+ CD16++) have all been linked to CVD. In fact, classical130 and 
intermediate131 monocytes have been defined as independent risk predictors of 
CVD in separate cohorts, whereas CD16+ monocytes have been correlated to mean 
intima-media thickness130.  Moreover, recent research has shown that each 
monocyte subpopulation has distinct functions, e.g. classical and intermediate 
monocytes were shown to have high phagocytic capacities, whereas non-classical 
monocytes only had a limited phagocytic activity132. Characterizing the monocyte’s 
functional phenotype using our HCA platform could help to determine how 
monocyte origin affects their functional profile, and whether monocytes from AMI 
patient are more prone to differentiate into functionally distinct macrophages than 
healthy patients. This could also help us to reveal and interfere with relevant 
mechanistic pathways involved in the differentiation of monocytes to functionally 
diverse macrophages.  
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Concluding remarks 
In this thesis, we have developed a ready-to-use, high-content analysis platform 
able to detect macrophage functional heterogeneity in the context of CVD 
inflammation. This platform is constantly being improved and expanded by 
including other relevant macrophage functions, and by incorporating 
functionalities of other cell types relevant to atherosclerosis. In addition, we have 
proven that this platform can be deployed in different settings, such as the 
development of a reference map of macrophage functional activation, or in 
detection of AMI-linked macrophage functional and transcriptional signatures, 
opening new avenues for therapeutic research.  
Macrophages transcriptional plasticity is now widely acknowledged, which has 
refashioned the previous oversimplified M1/M2 activation view. Using high content 
cell imaging, we demonstrated that macrophage transcriptional diversity has direct 
repercussions at the functional level. Furthermore, we revealed specific gene 
expression patterns linked to unique functions. This allowed us to build a unique 
function-based macrophage atlas. This atlas could, in the future, be used to directly 
predict macrophage functional activity in responses to drugs based on gene 
expression profile, and thus rapidly study drug efficacy.  
Aside from their important role in atherosclerosis development and progression, 
macrophages are also key players in AMI repair. Exposure of monocyte-derived 
macrophages to AMI systemic environment appears to affect macrophage 
functions and this is also reflected in the transcriptional patterns. Furthermore, we 
successfully detected specific transcriptional programs associated with certain 
macrophage functions and poor prognosis.  
Lastly, using our platform, we studied the functional implication of newly 
discovered biomarkers for the development of obesity-related CVD. Studying the 
causal relationship of biomarkers with CVD inflammation could help at discovering 
new therapeutic targets.  
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Summary 
Cardiovascular diseases, mainly driven by atherosclerosis, are the leading cause of 
death in the world. Atherosclerosis is a chronic inflammatory and lipid-driven 
vascular disease, where inflammatory cells, lipids and fibrous tissue progressively 
accumulate in the inner wall of the arteries, forming an atherosclerotic plaque that 
can eventually rupture. This might restrict blood flow and cause myocardial 
infarction and/or stroke. Macrophages are instrumental in a variety of 
cardiovascular diseases, as they not only are the most abundant immune cell type 
in atherosclerosis, but also play a central role in ischemia-reperfusion injury and 
healing in the heart. Moreover, they are known to contribute to the low-grade 
inflammation typical of cardiometabolic diseases. The transcriptional 
heterogeneity and plasticity of macrophages have widely been demonstrated. 
However, to date, evidence of functional plasticity and its link to transcriptional 
activity is still missing. Having a detailed description of macrophage functional 
heterogeneity could help to understand their exact role under pathological 
condition. Therefore, in this dissertation, we examined the functional diversity of 
macrophages in the context of cardiovascular inflammation, such as 
atherosclerosis, acute myocardial infarction and cardiometabolic disease, and their 
potential role as disease sensors.  
In chapter 2, we built a high-throughput platform able to detect key functions of 
macrophages in the context of cardiovascular inflammation. We developed and 
downscaled functional assays, all based on fluorescent probes, to detect a total of 
19 functions, i.e. phagocytosis and apoptosis. We were able to show that 
macrophage transcriptional plasticity is directly translated to functional 
heterogeneity. Additionally, we generated a function-based atlas of human 
monocyte derived macrophage responses to a variety of established stimuli using 
our in vitro platform. The functional activation map can serve as a reference for 
future research on macrophage heterogeneity, but also to position disease-
associated changes in functional pattern.  
Next to their importance in atherosclerosis, macrophages are also key players of 
acute myocardial repair. Chapter 3 investigated the use of our novel high-
throughput platform to study the impact of systemic status of patients that suffered 
an acute myocardial infarction on macrophages. We discovered that, after 
exposure to acute myocardial infarction patient serum, macrophages exert specific 
functions, reflecting their activation state and cellular stress level. Moreover, RNA 
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sequencing analysis revealed specific genes highly correlating with acute 
myocardial infarction phenotype and clinical progression of the patient. Our results 
thus show that serum of patients with and acute myocardial infarction reprograms 
macrophage functionality, and this could help to understand how disease-
compromised functions can have direct consequences on disease prognosis. This 
opens the way for new therapies to correct adverse functional changes.  
In chapter 4, we described the use of the platform to examine functionality of 
macrophages after depleting an anti-apoptotic protein, Mcl-1, in a mouse model of 
atherosclerosis.  Using our high-throughput platform, we showed that, 
macrophages lacking Mcl-1 showed a clear phenotype of increased lipid uptake 
capacity and apoptosis, which aligns with the phenotypic effects we observed in 
mice with Mcl-1 myeloid deficiency. Furthermore, we developed a novel assay for 
the platform to study the formation of giant cells, a hallmark of macrophages 
lacking Mcl-1 in our study.  
In chapter 5, we studied the causal relationship of novel obesity-related CVD 
biomarkers and macrophage functions using our high-throughput platform. Obesity 
is one of the main risk factors of CVD, as it is linked to abnormal blood lipid profiles, 
and conventional classifiers for CVD are not accurate enough in risk prediction. 
Therefore, we performed lipidomics on two independent obese cohorts and 
discovered a new lipid signature, able to accurately predict disease outcome. We 
measured the functional profile of macrophages after exposure to these novel 
biomarkers and identified phenotypic changes, such as phagocytosis, hinting to a 
causal involvement in the disease process and rendering them potential 
therapeutic target for obesity-related CVD.  
Finally, chapter 6 addressed the main findings of this thesis and discusses their 
implications and future perspectives. This dissertation suggested that the novel 
platform able detect measure macrophage functional plasticity could, in the future, 
help to study the implication of macrophages in atherosclerosis and drug 
development.  
Altogether, this thesis provided novel insights into the functional diversity of 
macrophages in cardiovascular disease inflammation, such as atherosclerosis, 
acute myocardial infarction and cardiometabolic diseases using a ready-to-use 
high-content analysis platform.   
Summary | 7 
Page | 205  
 
Samenvatting 
Cardiovasculaire aandoeningen, voornamelijk het gevolg van aderverkalking, zijn 
de belangrijkste doodsoorzaak wereldwijd. Aderverkalking is een chronische 
ontsteking van de vaatwand, waarbij ontstekingscellen, vetten en fibreus materiaal 
zich opstapelen in de binnenste laag van een bloedvat. Dit leidt tot de vorming van 
een atherosclerotische plaque die uiteindelijk kan scheuren, wat de 
bloeddoorstroming kan beperken en een hartinfarct en/of beroerte kan 
veroorzaken. Macrofagen zijn van belang bij verschillende cardiovasculaire 
aandoeningen; niet alleen zijn ze het meest voorkomende celtype bij 
aderverkalking, ze spelen ook een centrale rol bij ischemia-reperfusie schade en 
herstelprocessen in het hart. Daarenboven is bekend dat ze bijdragen aan de 
laaggradige ontsteking kenmerkend voor cardiometabole aandoeningen. De 
transcriptionele verscheidenheid en de plasticiteit van macrofagen zijn uitvoerig 
aangetoond. Tot op vandaag is er echter geen bewijs voor een functionele 
plasticiteit en de daarbijhorende brug naar transcriptionele activiteit. Een 
gedetailleerde beschrijving van de functionele verscheidenheid van een macrofaag 
zou zijn precieze rol in ziekteprocessen kunnen verduidelijken. Om die reden 
hebben we in deze verhandeling de functionele diversiteit van macrofagen in de 
context van cardiovasculaire ontstekingsziekten, zoals aderverkalking, hartinfarct 
en cardiometabole aandoeningen, onderzocht, alsmede hun mogelijk gebruik als 
ziekte-sensoren.  
In hoofdstuk 2 bouwden we een high-throughput platform dat sleutelfuncties van 
macrofagen in een cardiovasculaire ontstekingscontext kan detecteren. We 
ontwikkelden en miniaturiseerden functionele testen, gebaseerd op fluorescente 
detectiemoleculen, zodat in totaal 19 functies, bijvoorbeeld fagocytose en 
apoptose, gemeten konden worden. We konden aantonen dat de transcriptionele 
plasticiteit in een macrofaag rechtstreeks relateert aan zijn functionele 
verscheidenheid. Daarnaast genereerden we met behulp van ons in vitro platform 
een op functie gebaseerde atlas van de reactiepatronen van humane monocyt-
afgeleide macrofagen op een diverse set gekende stimuli. De functionele 
activatiekaart kan dienst doen als referentie voor toekomstig onderzoek naar 
macrofaag heterogeniteit, en ook als basis om ziekte-gerelateerde veranderingen 
in het functionele patroon op te positioneren.  
Naast hun belangrijke rol in aderverkalking zijn macrofagen ook kritische spelers in 
het herstellen van het beschadigde hart na infarct. Hoofdstuk 3 onderzocht of ons 
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nieuwe high-throughput platform geschikt was om de impact van de systemische 
omgeving van hartinfarctpatienten op macrofagen te bestuderen. We ontdekten 
dat macrofagen, na blootstelling aan serum van hartinfarctpatienten, specifieke 
functies vervulden die overeenkwamen met hun activatiestatus en cellulaire 
stressniveau. Daarenboven identificeerde RNA sequencing analyse bepaalde genen 
die heel sterk correleerden met het hartinfarct fenotype en met de klinische 
prognose van de patient. Onze resultaten laten zien dat het bloed van 
hartinfarctpatienten macrofagen programmeert tot het vervullen van andere 
functies. Ze kunnen bijdragen aan een beter begrip van hoe bepaalde functies die 
door ziekte worden gecompromitteerd onmiddellijke gevolgen kunnen hebben 
voor het verdere ziekteverloop. Dit zet de deur open naar nieuwe behandelingen 
die de ongewenste functionele veranderingen tegengaan.  
In hoofdstuk 4 beschrijven we gebruik van het platform om macrofaag 
functionaliteit te onderzoeken nadat een anti-apoptotisch eiwit, Mcl-1, werd 
verwijderd in een muizenmodel van aderverkalking. Met behulp van het  high-
throughput platform bewezen we dat macrofagen die Mcl-1 misten een duidelijk 
verhoogde vetopname capaciteit en verhoogde celdood vertoonden, gelijkaardig 
aan het fenotype geobserveerd in muizen met Mcl-1 deficientie in myeloide cellen. 
Daarnaast ontwikkelden we een nieuwe functionele test die aan het platform werd 
toegevoegd: de vorming van veelkernige reuzencellen, een in het oog springende 
eigenschap van de Mcl-1 deficiente macrofagen in deze studie.  
In hoofdstuk 5 bestudeerden we het oorzakelijk verband tussen nieuwe biomarkers 
voor overgewicht-gerelateerde cardiovasculaire aandoeningen en macrofaag 
functies met behulp van ons high-throughput platform. Overgewicht is een van de 
belangrijkste risicofactoren voor cardiovasculaire ziekten omdat het samenhangt 
met abnormale lipidenprofielen in het bloed. Standaard beslismodellen zijn hier 
niet voldoende accuraat in het voorspellen van cardiovasculair risico.  Om die reden 
hebben we lipidomics uitgevoerd in twee onafhankelijke cohorten van mensen met 
overgewicht. We ontdekten een nieuwe lipidensignatuur die met grote precisie 
voorspelde hoe de ziekte verder verliep. We maten het functionele profiel van 
macrofagen na blootstelling aan deze nieuwe biomarkers en identificeerden 
fenotypische veranderingen, bijvoorbeeld in fagocytose, wat er mogelijks op wijst 
dat deze biomarkers oorzakelijk betrokken zijn in het ziekteproces en dus 
kandidaten kunnen zijn in het behandelen van overgewicht-gerelateerde 
cardiovasculaire aandoeningen. 
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Hoofdstuk 6 tenslotte keek terug op de belangrijkste bevindingen van deze thesis 
en bespreekt hun implicaties en toekomstperspectieven. Deze verhandeling 
suggereerde dat het nieuwe platform dat de functionele plasticiteit van 
macrofagen in kaart kan brengen in de toekomst zou kunnen worden ingezet om 
de betrokkenheid van macrofagen in aderverkalking en medicijnontwikkeling te 
bestuderen.  
Samenvattend verschaft deze thesis nieuwe inzichten in de functionele diversiteit 
van macrofagen in cardiovasculaire aandoeningen, zoals aderverkalking, hartinfarct 
en cardiometabole ziekten, door gebruik te maken van een operationeel high-
content analyse platform. 
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Résumé 
Les maladies cardiovasculaires, souvent causées par des plaques d’athérome, sont 
la principale cause de décès dans le monde. L’athérosclérose est une maladie 
vasculaire inflammatoire chronique dans laquelle des cellules inflammatoires, des 
lipides et des tissus fibreux s’accumulent progressivement dans la paroi interne des 
artères, formant une plaque d’athérome qui risque de finalement se rompre. Le 
flux sanguin est alors restreint et peut causer un infarctus du myocarde et/ou un 
accident vasculaire cérébral. Les macrophages ont un rôle déterminant dans 
plusieurs maladies vasculaires, car ils constituent non seulement le type de cellules 
immunitaires le plus abondant dans les plaques d’athérome, mais ont aussi un rôle 
central dans les lésions d’ischémie-reperfusion et la régénération des tissus 
cardiaques. Ils sont également connus pour contribuer à la légère inflammation 
caractéristique des maladies cardiométaboliques. L’hétérogénéité 
transcriptionnelle et la plasticité des macrophages ont été largement démontrées. 
Cependant, à ce jour, aucune preuve de plasticité fonctionnelle liée à leur activité 
de transcription n’a été prouvée. L’accès à une description détaillée de 
l’hétérogénéité fonctionnelle des macrophages pourrait aider à mieux comprendre 
leur rôle précis dans le développement de maladies cardiométaboliques. Par 
conséquent, dans cette thèse, nous avons étudié la diversité fonctionnelle des 
macrophages dans le contexte des maladies cardiovasculaires, telle que 
l’athérosclérose, l’infarctus aigu du myocarde et les maladies cardiométaboliques. 
Dans le chapitre 2, nous avons développé une plateforme à haut débit capable de 
détecter certaines fonctions clés des macrophages dans le contexte de 
l’inflammation cardiovasculaire. Nous avons mis au point des tests fonctionnels, 
tous basés sur des sondes fluorescentes, afin de détecter un total de 19 fonctions, 
telles que la phagocytose ou l’apoptose. Nous avons démontré que la plasticité 
transcriptionnelle des macrophages est directement traduite en hétérogénéité 
fonctionnelle. De plus, en utilisant notre plateforme in vitro, nous avons généré un 
atlas de fonctionnalités de macrophages, dérivés de monocytes humains, qui 
répertorie leur réponse à une variété de stimuli. Ce spectre d’activation 
fonctionnelle pourra servir de référence pour des recherches futures sur 
l’hétérogénéité des macrophages, mais également pour classer les changements de 
fonction associés à certaines maladies dans notre atlas. 
En plus de leur importance dans l’athérosclérose, les macrophages sont également 
des acteurs clés de la cicatrisation cardiaque à la suite d’un infarctus aigu du 
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myocarde. Dans le chapitre 3 nous avons utilisé notre nouvelle plateforme à haut 
débit pour étudier l’impact de l’état systémique des patients ayant subi infarctus 
du myocarde aigu sur les macrophages. Nous avons découvert qu’après être avoir 
été exposés au sérum de patients souffrant d’un infarctus aigu du myocarde, les 
macrophages exerçaient des fonctions spécifiques reflétant leur état d’activation 
et leur niveau de stress cellulaire. De plus, l’analyse du séquençage de l’ARN a 
révélé des gènes spécifiques étroitement corrélés au phénotype d’infarctus aigu du 
myocarde et à l’évolution clinique du patient. Nos résultats montrent donc que le 
sérum des patients atteints d’un infarctus aigu du myocarde reprogramme la 
fonctionnalité des macrophages. Cela pourrait aider à comprendre comment les 
dysfonctions cellulaires liées à certaines maladies peuvent avoir des conséquences 
directes sur le pronostic de la maladie et aider à développer de nouvelles solutions 
thérapeutiques pour rétablir les fonctions cellulaires.  
Dans le chapitre 4, nous avons décrit l’utilisation de cette plateforme pour analyser 
la fonctionnalité des macrophages suite à la déplétion d’une protéine anti-
apoptotique, Mcl-1, dans un modèle murin d’athérosclérose. En utilisant notre 
plateforme à haut débit, nous avons démontré que les macrophages dépourvus de 
Mcl-1 présentaient un phénotype précis d’augmentation de la capacité 
d’absorption des lipides et d’apoptose, ce qui correspond aux effets phénotypiques 
observés chez les souris présentant un déficit myéloïde en Mcl-1. De plus, nous 
avons développé un nouveau test pour la plateforme permettant d’étudier la 
formation de cellules géantes, caractéristique des macrophages dépourvus de Mcl-
1 dans notre étude.  
Dans le chapitre 5, nous avons étudiés la relation de cause à effet entre nouveaux 
marqueurs biologiques pour le développement de maladies cardiovasculaires et 
macrophages chez les obèses, en utilisant notre plateforme à haut débit. L’obésité 
est l’un des principaux facteurs de risque des maladies cardiovasculaires, car elle 
est liée à des profiles lipidiques sanguins anormaux, et les marqueurs classiques des 
maladies cardiovasculaires ne permettent pas une prédiction du risque 
suffisamment précise. Par conséquent, nous avons effectué une analyse 
lipidomique sur deux cohortes indépendantes obèses et avons découvert une 
nouvelle signature lipidique, capable de prédire avec précision l’évolution de la 
maladie. Nous avons mesuré le profil fonctionnel des macrophages après 
exposition à ces nouveaux marqueurs biologiques et identifié des modifications 
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phénotypiques, telles que la phagocytose, suggérant une implication causale dans 
le processus de la maladie.  
Enfin, le chapitre 6 a traité des principales conclusions de cette thèse et discuté de 
leurs implications et perspectives. Cette thèse suggère que la nouvelle plateforme 
capable de détecter et mesurer la plasticité fonctionnelle des macrophages 
pourrait, à l’avenir, aider l’étude de l’implication des macrophages dans les 
maladies cardiovasculaires et le développement de médicaments.  
En conclusion, cette thèse a fourni de nouvelles informations sur la diversité 
fonctionnelle des macrophages dans le contexte de l’inflammation vasculaire liées 
au pathologies cardiovasculaires, telles que l’athérosclérose, l’infarctus aigu du 
myocarde et les maladies cardiométaboliques en utilisant une plateforme d’analyse 
à haut débit prête à l’emploi.  
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Valorization, defined as a “process that aims at enhancing societal impact”1, is an 
important aspect of (academic) research. It is crucial for scientists to make the 
knowledge acquired during a PhD available and accessible to society both by 
transferring the results to potential stakeholders (e.g. pharmaceutical companies 
or other research centers) and if opportune, by translating them into possible news 
products that society could benefit from. In this chapter, we will present how the 
work described in this thesis has and will be transferred to society and how it, in 
the future, could help to reduce the socio-economic burden of cardiovascular 
disease.  
Cardiovascular disease 
Cardiovascular disease (CVD), mainly driven by atherosclerosis, is still the leading 
cause of death in the world2. In 2016, almost 18 million people died from CVDs 
globally, mostly attributable to coronary artery disease and stroke3. CVD has 
become an obvious economic burden, as the European Heart Network has 
estimated the total CVD-related cost to be €210 billion per year2. The main costs 
generated from CVD are related to healthcare of CVD patients (healthcare, 
medication, hospitalization), but also indirect costs, such as patient work 
productivity loss and intangible costs, e.g. costs of pain and suffering, are 
substantial. This highlights the need to rapidly discover new therapies or strategies 
to cure and study CVD. CVD research centers on two major topics: (1) investigations 
on mechanistic pathways involved in the pathophysiology of CVD; (2) translational 
studies aimed at CVD diagnosis, prevention and intervention, often based on 
findings from the basic science studies. In this thesis, we aimed to cover both areas 
of research, with chapter 3 and 5 focusing on prediction and prevention of CVD, 
and chapter 2 to 4 mainly focusing on understanding functional pathways involved 
in CVD inflammation.  
As described above, valorization can be accomplished via two main tracks: “societal 
transfer of results” and “economical transfer”. We have achieved the former by 
presenting the main results described in this thesis at (inter)national conferences. 
In addition, making scientific knowledge accessible to everyone is another key 
aspect of societal transfer. During my PhD, I was selected to give a Ted-talk at the 
PhD-student course organized by the Dutch Heart Foundation in 2017, improving 
my communication skills to present scientific research to a non-scientific audience. 
We further intend at disseminating the acquired knowledge to cardiovascular 
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patients by giving lectures via the Harteraad (https://www.harteraad.nl/). 
Moreover, we aim at publishing the main results of this thesis in peer-reviewed, 
preferably open access, scientific journals; in fact chapter 4 has already been 
published in an open-access journal, and chapter 5 is under review at European 
Heart Journal. Datasets will be deposited in repositories that are publicly available, 
such as GEO. The published results could then be used as starting point or reference 
for the scientific community in future research. As to the second track, the 
translation of results into potential diagnostic or therapeutic strategies to detect 
and treat CVD, we aim at conducting an active Intellectual Property IP protection 
strategy to allow successful knowledge exploitation of the projects described in this 
thesis. Together with carefully selected external partners, such as biotech 
companies, we will develop a cost-effective utilization strategy of, for example, our 
MacroScreen platform or our predictive lipid-signature. The below paragraphs will 
expand the different valorization opportunities of the main results of this thesis. 
Bringing the predictive lipid signature to the market  
In chapter 5, we have profiled circulating lipids in two independent obese patient 
cohorts and built a prediction model of future CVD. Obesity is a well-known risk 
factor for CVD; it accounts for approximately 30% of the cases4. This is explained by 
the “bi-angular relationship” between CVD and obesity; obesity is both directly and 
indirectly linked to CVD due to the abnormal blood lipid profile and to its relation 
to other important risk factors of CVD, such as hypertension and diabetes, 
respectively.  However, current risk factors, such as cholesterol levels, blood 
pressure or glucose levels, lack predictive power for the development of CVD in the 
obese population to be useful for individual risk assessment. The lipid-signature 
described in chapter 5, has unprecedented predictive power for future CVD and 
could be a valuable tool for early detection of high-risk obese patients, motivating 
them to lifestyle changes, instead of costly life-long medication, such as statins, or 
pricey surgical operations, thereby reducing the economic burden of CVD.  
Current risk prediction is performed by calculating risk scores, based on many 
clinical parameters. Ideally, our multi-lipid CVD risk signature could be translated 
into a fast and accurate in vitro diagnostic (IVD) test for plasma samples of obese 
patients, which then would be used in the clinics to further help in individual CVD 
prediction. However, translating these findings to an accurate IVD test requires 
further study to prove the diagnostic value of our prediction model. First, future 
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studies will have to reproduce and validate these findings in even larger cohorts, as 
patient numbers still were rather limited for both our discovery (n=78) and 
validation cohort (n=200). Second, current lipid profiling is performed using mass 
spectrometry. This technique requires specialized infrastructure and is expensive 
and time-consuming, making it not feasible for point-of-care testing. Therefore, 
further studies aim at developing an IVD assay, which could for example rely on 
aptamer technology, to detect our lipid signature. Aptamers arrays are spotted with 
single strand DNA or RNA (ssDNA/ssRNA), that have a unique tertiary structure able 
to specifically bind to a single lipid5 and have already showed their potential for 
biomarker discovery6. Together with specialized companies, such as Novaptech or 
Eurogentec, which have experience with production of aptamer-based arrays for 
diagnostic purposes, we will develop and validate a diagnostic product at different 
location sites and on a high number of biological samples. This easy-to-use 
diagnostic tool could directly be used by general practitioners and in the hospital, 
and lead to early identification of high-risk CVD patients, early individualized 
intervention and CVD prevention. Next to this, this diagnostic tool will help monitor 
medical treatment efficacy and will be used as an outcome measurement for 
clinical trials and intervention studies.  
Potential therapeutic solutions  
Current medication for CVD involves lipid lowering therapy, including statins7, and 
antihypertensive treatment. Despite their effectiveness with a 20% reduction in 
CVD risk, lipid lowering therapies are unable to prevent future cardiovascular 
events in a significant number of patients8. More recently, intervention in IL-1β 
signaling with a monoclonal antibody on top of statin treatment, in subjects with 
low grade inflammation led to a supplementary reduction of 14% in CVD incidence9. 
However, this was accompanied by increased infection numbers and, importantly, 
no difference in overall mortality was observed after IL-1β antibody treatment. This 
emphasizes the need to discover new therapeutic targets to decrease CVD risk and 
develop new diagnosis tools to enable detection of high-risk profile at a reversible 
stage of the disease. 
In chapter 5, we discovered an 18-lipid signature predicting the incidence of CV 
events in the obese population. Using our MacroScreen platform, we could show 
that some of our lipid predictors were affecting key functions of macrophages, the 
main immune cell type implicated in atherosclerosis, hinting at a possible causal 
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relationship. Moreover, these lipids were enriched in unstable, as compared to 
stable human atherosclerotic plaques. Future research aims at studying the 
implication of these lipids in disease development and progression, by interacting 
with their synthesis in vivo for example. This could potentially lead to the discovery 
of new key players in atherosclerosis related CVD and, subsequently, open new 
avenues for therapeutic solutions. As statins fail at reducing the risk in a majority 
of patients, despite their profound effect on cholesterol and, indirectly, on other 
lipids levels10, novel drugs should be generated. To target specific lipids, one could 
think of generating molecules interacting with their synthesis pathway by inhibiting 
a key enzyme, for example. 
Another potential target for future intervention was unveiled in Chapter 4, where 
we investigated the impact of a deficiency of Mcl-1, an anti-apoptotic protein, on 
atherosclerosis. We were able to convincingly show that Mcl-1 is essential for 
survival of macrophages, as well as neutrophils. Additionally, Mcl-1 was implicated 
in macrophage lipid uptake and subsequent macrophage fusion capacity, resulting 
in the formation of multinucleated giant cells (MGCs). Evidence for the presence of 
MGCs in human atherosclerotic plaques is scarce; and the description of a clear role 
in the pathogenesis of disease is lacking. One study described MGCs to express high 
level of cathepsins, enabling the rupture of the elastic lamina and facilitating the 
migration of smooth muscle cells during atherosclerosis11. Clearly, more research is 
needed to understand the implication of MGCs in atherosclerosis and their exact 
role in disease development and progression. Second, small molecules targeting 
Mcl-1 already exist, as  Mcl-1 is an interesting target to treat cancer, due its high 
expression in tumor cells and role in cell survival12,13. However, as we showed, 
targeting Mcl-1 in an animal model of atherosclerosis led to severe neutropenia, 
and had no effect on atherosclerotic lesion size. Therefore, targeting Mcl-1 will 
most probably not lead to successful therapeutic strategies; yet, this could be used 
as a model of neutropenia or giant-cell enriched atherosclerosis to further 
investigate MGCs implication in atherosclerosis.  
Novel human centered validation strategies in CVD research  
Funding for cardiovascular disease research is sizable14. Between 2010 and 2012, 
funding for CVD research (both academic and in private company setting) 
amounted around €876 million in Europe14.  CVD research is nowadays mainly 
performed on animal models, which are expensive, and time consuming and do 
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not, in every aspect, represent human disease. Therefore, building a humanized 
test platform to capture cardiovascular inflammation, such as atherosclerosis and 
AMI, in vitro (chapter 2 to 5) could help reducing the costs of CVD fundamental 
research and drug development. First, chapter 2 showed that macrophages are 
functionally reprogrammed after exposure to various stimuli, such as several 
cytokines or fatty acids. This led to the identification of a macrophage activation 
functional map, which could serve as reference for further studies. Second, chapter 
3 investigated the functional responses of macrophages after exposure to AMI 
patient serum. We observed that macrophages functionally respond to AMI 
systemic environment and these functionalities were also linked to poor prognosis, 
four months after the infarct, showing the potential utility of this platform as a fast 
and cheap drug screening platform. One could think of assessing the effect of 
compound libraries on key functions of macrophages related to AMI systemic 
environment, and subsequently select the most interesting target for further 
analysis. Importantly, our platform will never serve a diagnostic purpose, as it is too 
time-consuming and labor intensive for clinical use.  
Altogether, this demonstrates that our platform has great potential to quickly study 
the implication of macrophages in CVD inflammation and to screen for modulators 
of critical macrophage functions for drug development purposes. The platform is 
ready-to-use, however future research aims at improving its physiological 
complexity, as it is currently based on two-dimensional monolayers of cells and this 
lacks the cell-cell interaction and 3-dimension aspects of the human body.   
Conclusion 
In conclusion, the work presented in this thesis aimed to tackle the socio-economic 
burden of CVD at several levels. We have developed a new tool, able to characterize 
macrophage functions in the context of CVD inflammation. This tool could, in the 
future, help reduce the use of animal models and improve the translational 
problem linked to animal studies. Furthermore, we have identified a predictive lipid 
signature for the development of obesity related CVD, which shows promise for 
stratifying obese individuals with increase CVD risk and may also have therapeutic 
potential. Lastly, we have investigated the impact of Mcl-1 in atherosclerosis, and 
its implication in giant cell formation opening new avenues to manipulate MGC 
formation in atherosclerosis, and potentially other diseases where MGCs play a role
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2D 2-dimensional 
3D 3-dimensional 
AMI Acute myocardial infarction 
AT Adipose tissue 
ASC Apoptosis-associated speck like 
AUC area under the curve 
ABCA1 ATP binding cassette A1 
B-cell B lymphocyte 
BP blood pressure 
BMI Body mass index 
BMDM Bone marrow derived macrophage 
BMT Bone marrow transplantation 
CRP C reactive protein 
CCA Canonical correlation analysis 
CVD Cardiovascular disease 
CEA Carotid endarterectomy 
CER Ceramide 
CCL Chemokine (C-C motif) ligand 
CXCL Chemokine (C-X-C motif) ligand 
CXCR Chemokine (C-X-C motif) receptor 
CE Cholesteryl ester  
CD Cluster of differentiation 
CODAM Cohort on Diabetes and Atherosclerosis Maastricht 
CAD Coronary artery disease 
CHD Coronary heart disease 
CCM Correlation coefficient matrix 
DC dendritic cell 
DM  diabetes mellitus 
DAG Diacylglycerol 
EC Endothelial cells  
FH Familial hypercholesterolemia  
FCS Fetal calf serum 
FRS Framingham study 
GO Gene ontology 
GWAS Genome wide association study 
GC Glucocorticoids 
GM-CSF Granulocyte macrophage colony stimulating factor 
HE Hematoxylin and eosin 
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HCA high content analysis 
HDL High-density lipoprotein 
iMacs Iduced pluripotent stem cells derived macrophages 
IC Immune complexe 
iPSC Induced pluripotent stem cells 
IFNβ Interferion-β 
IFNg Interferon-g  
IL Interleukin 
KO Knock-out 
LA Lauric acid 
LiA Linoleic acid 
LPS Lipopolysaccharide 
LR  Logistic regression 
LDL Low-density lipoprotein 
LDLR Low-density lipoprotein receptor 
LPC Lysophosphaditycholine 
LPA Lysophosphatidic acid 
M-CSF Macrophage colony stimulating factor 
MMP Metalloprotease 
mtDNA Mitochondrial DNA 
MAG Monoacylglycerol 
MCP-1 Monocyte chemoattractant protein 1 
MDM Monocyte-derived macrophage 
MGC Multinucleated giant cell 
Mcl-1 Myeloid cell leukemia 1 
MI Myocardial infarction 
NK Natural killer cell 
NET Neutrophil extracellular trap 
NMOC Non-mitochondrial oxygen consumption 
NLR Nucleotide-binding oligomerization domain-like receptors 
ORO Oil Red O  
OA Oleic acid 
oxLDL oxidized low-density lipoprotein 
PA Palmitic acid 
P3C Pam3CSK4 
PLS-DA Partial least square discriminant analysis 
PAMP Pathogen associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
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PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PMN Polymorphonuclear leukocyte 
PCA Principal componenet analysis 
PCSK9 Proprotein converstase subtilisin/kexin type 9 
PGE2 Prostaglandin E2 
RF Random forest 
ROS Reactive oxygen species 
qPCR Real time polymerase chain reaction 
ROC Receiver operator characteristic 
RPMI  Roswell park memorial institute medium 
SMC Smooth muscle cell 
SM Sphingomyelin 
SD Standard deviation 
SEM Standard error of the mean 
sLPS Standard LPS 
SA Stearic acid  
SHIP Study of Health in Pomerania 
SVM Support vector machine 
T-cell T lymphocyte 
TUNEL Terminal deoxytransferase dUTP nick-end labeling 
3D Three dimensions 
TPP TNF+PGE2+P3C 
TC Total cholesterol 
TAG Triacylglycerol 
TG Triglycerides 
TAM Tumor associated medium 
TNF-α Tumor necrosis factor α 
2D Two dimensions 
T2DM Type 2 diabetes mellitus 
upLPS Ultra-pure LPS 
VCAM Vascular cell adhesion molecule 
vSMC Vascular smooth muscle cell 
VLDL very-low density lipoprotein 
WGCNA Weighted gene co-expression network analysis 
WTD Western type diet 
WBC White blood cells 
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WT Wild type 
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taught me so much in the last four years and I am grateful to you for many reasons. 
First, you have allowed me to develop personally and professionally, by giving me 
the opportunity to (quickly) be independent on several (challenging) projects. You 
have never doubted about my abilities and supported me in all the directions I was 
taking. Our countless number of meetings have inspired me, and I was always 
impressed by how much you know about… everything (even though sometimes I 
had no idea what you were talking about… Oops). As we agreed on many times, my 
PhD journey has been a bumpy road, very bumpy at times, but having you as 
promoter kept me motivated throughout! Thank you for that! 
The second ones to thank are of course Dr. Temmerman and Dr. Sluimer. Lieve and 
Judith, my two “doctor mamas”! Where to start? Lieve, you have found me in the 
hallway waiting for Erik, on my first day! And from that moment on, you never let 
me go! you have taught me everything about the HCA, lab work, macrophages, and 
many more topics (maybe not about organizational skills though… hihi) and we’ve 
spent a lovely four years working together. We were forming the Belgian HCA team, 
training others, performing tons of experiments together, answering questions 
with the exact same answers at the exact same time (great minds think alike!). We 
have worked hard on five projects together, and your scientific input, optimism and 
rationality have greatly helped me to move forward! Judith… In the first six months 
of my PhD, I was waiting for Erik to name a co-promoter and I have to admit that I 
was secretly hoping it would be you! Lucky me, you were the one and even though 
your evil look and frank honesty were a bit scary at first, being part of the “Eggplant 
team” or “teamplayers family” was one of the best things that happened during my 
PhD. You are a driven and inspiring scientist; your help and input were greatly 
appreciated. Next to the scientific part, you are a wonderful person, who listened 
and comforted me in hard times! Thank you for all this!  
I would also like to thank all the members of my assessment committee Prof. 
Schurgers, Prof. Kersten, Prof. Lutgens, Dr. van den Akker and Dr. Coort for taking 
the time to read and assess my thesis.  
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Prof. Dr. Zur Hausen, thank you for having me in your department in the last four 
years and the countless compliments about my (very French) first name!   
Thank you to STW and all the members of the user committee. Dr. Schalkwijk, 
thank you for the interactive discussions during the STW meetings. Dr. Mengerink, 
thank you for teaching me all about mass spectrometry.  
Thank you to all the co-authors for their contribution to each chapter of this thesis 
My par(ty)anymphs… Lauren and Kim! Shister and Kiki, the Kilamas… WHAT A 
JOURNEY TOGETHER! Let’s start with Lauren… haha I’m laughing just by thinking of 
our story. We met on the 3rd of December 2015 and I (don’t) remember it well! It 
involved alcohol (Alcohooool, alcohoooooool), as everything we did from that day 
on! You rapidly became my buddy! We did EVERYTHING together, day and night 
drinking (or 24h long drinking!), traveling to Paris, Switzerland and New Jersey, 
organizing cool events for I’MCARIM, watching millions (or almost) of movies at 
Pathé, dancing like crazy at VBML with our socks (DOBBY IS A FREE ELF!). You have 
made my time in Maastricht amazing and unforgettable and I am very lucky to have 
you in my life!! My second paranymph, Kiki, as I once said, the only regret I have is 
that you did not start your PhD at the same time as me and that I only got to spend 
three years with you! But those three years were… epic! From the shy little Kim 
who began at Pathology, you became the confident and sometimes stubborn Kiki 
that I know. You were the mother of the KILAMA triangle, trying to guide both 
Lauren and me to the least stupid direction… From colleagues to roommates and 
best friend, you also taught me how to party well. You were always there for me, 
in good and bad times and I am so thankful for that! THANK YOU BOTH!  
Taghi, I have met you right after I started my PhD and we directly became friends. 
You have taught me everything about machine learning, programming (ish), 
prediction modelling, missing values, etc… Without you, the lipid project wouldn’t 
have been possible! Also, thank you for your support in hard times! Jan (Jean, 
Jeanette and so on), thanks for the parties, the macrophage stories, the bread-ice-
breaking questions and the 7am running session! It was a pleasure working with 
you, and I wish you all the best in the future! Jenny, the sweetest of all! Promise 
me one thing, you will always be that kind, smart and sexy woman I know! You rock 
girl, it was a pleasure having you around during my PhD. I wish you all the best in 
the future, and with your future husband Renzo! Dr. Jasper, thank you for all the 
thesis-writing tips, great parties and good fun in the lab! I hope your patients will 
be as fun as the pathology team! Enjoy your new life and let’s keep in touch! Olivia, 
I am so happy that you have found love and happiness here in Maastricht! You 
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deserve it, girl! Thank you for always listening to me and good luck with the end of 
your PhD! Adele, a hell of a good student who turned into a brilliant PhD candidate! 
Good luck with the monocyte project and take good care of the HCA! Han, thank 
you for all the graphs you generated for me! No matter the day or the time you 
were always there to help, and most of the nice graphs in this thesis come from 
you! Good luck with finishing your PhD! To all the “old” PhD students, Elke, Thomas, 
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